0001021408-24-004773.txt : 20240827 0001021408-24-004773.hdr.sgml : 20240827 20240827132959 ACCESSION NUMBER: 0001021408-24-004773 CONFORMED SUBMISSION TYPE: N-PX PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240827 DATE AS OF CHANGE: 20240827 EFFECTIVENESS DATE: 20240827 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Health Sciences Term Trust CENTRAL INDEX KEY: 0001785971 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-PX SEC ACT: 1940 Act SEC FILE NUMBER: 811-23466 FILM NUMBER: 241246675 BUSINESS ADDRESS: STREET 1: 100 BELLEVUE PARKWAY CITY: WILMINGTON STATE: DE ZIP: 19809 BUSINESS PHONE: 800 882 0052 MAIL ADDRESS: STREET 1: 100 BELLEVUE PARKWAY CITY: WILMINGTON STATE: DE ZIP: 19809 FORMER COMPANY: FORMER CONFORMED NAME: BlackRock Health Sciences Trust II DATE OF NAME CHANGE: 20190820 N-PX 1 primary_doc.xml N-PX RMIC LIVE 0001785971 XXXXXXXX false false N-2 06/30/2024 YEAR 2024 BlackRock Health Sciences Term Trust 800-882-0052

100 Bellevue Parkway Wilmington DE 19809

John Perlowski

50 Hudson Yards New York NY 10001

FUND VOTING REPORT N 811-23466 N 1 19 028-04295 000106614 801-47710 5493001LN9MRM6A35J74 BlackRock Advisors, LLC 0 BlackRock Health Sciences Term Trust John Perlowski John Perlowski Chief Executive Officer 08/27/2024 PROXY VOTING RECORD 2 proxyvote.xml IVERIC bio, Inc. 46583P102 US46583P1021 07/06/2023 To adopt the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc. ("Parent"), Berry Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), and Solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc., pursuant to which Merger Sub will merge with and into IVERIC, and IVERIC will become a wholly owned subsidiary of Parent (the "Merger"). EXTRAORDINARY TRANSACTIONS ISSUER 86080.000000 0 FOR 86080.000000 FOR IVERIC bio, Inc. 46583P102 US46583P1021 07/06/2023 To approve, by non-binding, advisory vote, compensation that may be paid or become payable by IVERIC to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 86080.000000 0 FOR 86080.000000 FOR IVERIC bio, Inc. 46583P102 US46583P1021 07/06/2023 To approve the adjournment of the special meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the special meeting. CORPORATE GOVERNANCE ISSUER 86080.000000 0 FOR 86080.000000 FOR Abcam Plc 000380204 US0003802040 07/12/2023 THAT Peter Allen be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 THAT Michael S. Baldock be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 THAT Sally W. Crawford be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 THAT in the event any director of the Company is appointed after the Company's receipt of the general meeting request dated May 30, 2023 and prior to this meeting, each such director be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 THAT Dr. Jonathan Milner, having consented to act, be appointed as Director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 THAT Dr. Jonathan Milner, having been appointed a Director of the Company, be further appointed to the position of Executive Chairman of the Company with immediate effect. CORPORATE GOVERNANCE SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 Appoint Two Additional Directors To The Board Whose Qualifications Will Include Significant Capital Allocation And Biotechnology Company Operating Experience CORPORATE GOVERNANCE SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 THAT the expenses incurred by Dr. Milner and those acting on his behalf in connection with his engagement with the Company in respect of the request to convene a general meeting be reimbursed by the Company. CORPORATE GOVERNANCE SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That Peter Allen be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That Michael S. Baldock be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That Sally W. Crawford be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That in the event any director of the Company is appointed after the Company's receipt of the general meeting request dated May 30, 2023 and prior to this meeting, each such director be removed from office as a director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That Dr. Jonathan Milner, having consented to act, be appointed as a Director of the Company with immediate effect. DIRECTOR ELECTIONS SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That Dr. Jonathan Milner, having been appointed a Director of the Company, be further appointed to the position of Executive Chairman of the Company with immediate effect. CORPORATE GOVERNANCE SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That it is the consensus of the shareholders that, promptly after the conclusion of this meeting, the Board of Directors shall conduct a thorough search for candidates and shall appoint at least two additional, independent, highly qualified Directors to the Board whose qualifications will include significant capital allocation and biotechnology company operating experience. CORPORATE GOVERNANCE SECURITY HOLDER 0.000000 193800.000000 Abcam Plc 000380204 US0003802040 07/12/2023 That the expenses incurred by Dr. Milner and those acting on his behalf in connection with his engagement with the Company in respect of the request to convene a general meeting be reimbursed by the Company. CORPORATE GOVERNANCE SECURITY HOLDER 0.000000 193800.000000 McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Richard H. Carmona, M.D. DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Dominic J. Caruso DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: W. Roy Dunbar DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: James H. Hinton DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Donald R. Knauss DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Bradley E. Lerman DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Linda P. Mantia DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Maria Martinez DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Susan R. Salka DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Brian S. Tyler DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Election of eleven directors for a one-year term: Kathleen Wilson-Thompson DIRECTOR ELECTIONS ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2024. AUDIT-RELATED ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 38905.000000 0 FOR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Advisory vote on the frequency of the advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 38905.000000 0 ONE YEAR 38905.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/21/2023 Submit Severance Agreement (Change-in-Control) to Shareholder Vote COMPENSATION SECURITY HOLDER 38905.000000 0 AGAINST 38905.000000 FOR Horizon Therapeutics Public Limited Company G46188101 IE00BQPVQZ61 07/27/2023 Election of Class III Director Nominees: Gino Santini DIRECTOR ELECTIONS ISSUER 75466.000000 0 FOR 75466.000000 FOR Horizon Therapeutics Public Limited Company G46188101 IE00BQPVQZ61 07/27/2023 Election of Class III Director Nominees: James Shannon, M.D. DIRECTOR ELECTIONS ISSUER 75466.000000 0 FOR 75466.000000 FOR Horizon Therapeutics Public Limited Company G46188101 IE00BQPVQZ61 07/27/2023 Election of Class III Director Nominees: Timothy P. Walbert DIRECTOR ELECTIONS ISSUER 75466.000000 0 FOR 75466.000000 FOR Horizon Therapeutics Public Limited Company G46188101 IE00BQPVQZ61 07/27/2023 Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023, and authorization of the Audit Committee to determine the auditors' remuneration. AUDIT-RELATED ISSUER 75466.000000 0 FOR 75466.000000 FOR Horizon Therapeutics Public Limited Company G46188101 IE00BQPVQZ61 07/27/2023 Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in this Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 75466.000000 0 FOR 75466.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Dr. Esther M. Alegria DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Richard C. Breeden DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Daniel A. Carestio DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Cynthia L. Feldmann DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Christopher S. Holland DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Dr. Jacqueline B. Kosecoff DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Paul E. Martin DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Dr. Nirav R. Shah DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Dr. Mohsen M. Sohi DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 Re-election of Directors: Dr. Richard M. Steeves DIRECTOR ELECTIONS ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending March 31, 2024. AUDIT-RELATED ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 To appoint Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law to hold office until the conclusion of the Company's next annual general meeting. AUDIT-RELATED ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 To authorize the Board of Directors of the Company or the Audit Committee of the Board of Directors to determine the remuneration of Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law. AUDIT-RELATED ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission, including the compensation discussion and analysis and the tabular and narrative disclosure contained in the Company's proxy statement dated June 7, 2023. SECTION 14A SAY-ON-PAY VOTES ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 To approve, on a non-binding advisory basis, whether the non-binding advisory vote on named executive officer compensation should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 158875.000000 0 ONE YEAR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 To approve a proposal renewing the Board of Director's authority to issue shares under Irish law. CAPITAL STRUCTURE ISSUER 158875.000000 0 FOR 158875.000000 FOR STERIS plc G8473T100 IE00BFY8C754 07/27/2023 To approve a proposal renewing the Board of Director's authority to opt-out of statutory pre-emption rights under Irish law. CAPITAL STRUCTURE ISSUER 158875.000000 0 FOR 158875.000000 FOR Legend Biotech Corporation 52490G102 US52490G1022 09/21/2023 To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2022. CORPORATE GOVERNANCE ISSUER 304632.000000 11400.000000 FOR 304632.000000 FOR Legend Biotech Corporation 52490G102 US52490G1022 09/21/2023 To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the "Independent Auditor") for the fiscal year ending December 31, 2023. AUDIT-RELATED ISSUER 304632.000000 11400.000000 FOR 304632.000000 FOR Legend Biotech Corporation 52490G102 US52490G1022 09/21/2023 To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years. DIRECTOR ELECTIONS ISSUER 304632.000000 11400.000000 FOR 304632.000000 FOR Legend Biotech Corporation 52490G102 US52490G1022 09/21/2023 To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years. DIRECTOR ELECTIONS ISSUER 304632.000000 11400.000000 FOR 304632.000000 FOR Legend Biotech Corporation 52490G102 US52490G1022 09/21/2023 To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years. DIRECTOR ELECTIONS ISSUER 304632.000000 11400.000000 FOR 304632.000000 FOR Legend Biotech Corporation 52490G102 US52490G1022 09/21/2023 To authorize each of the directors and officers of the Company to take any and every action that might be necessary to effect the foregoing resolutions as such director or officer, in his or her absolute discretion, thinks fit. CORPORATE GOVERNANCE ISSUER 304632.000000 11400.000000 FOR 304632.000000 FOR Reata Pharmaceuticals, Inc. 75615P103 US75615P1030 09/21/2023 To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the "Merger Agreement"), by and among Biogen Inc., a Delaware corporation ("Biogen"), River Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of Biogen ("Merger Sub"), and Reata Pharmaceuticals, Inc. ("Reata"), pursuant to which Merger Sub will be merged with and into Reata, with Reata surviving as a wholly-owned subsidiary of Biogen (the "Merger"). EXTRAORDINARY TRANSACTIONS ISSUER 100360.000000 50400.000000 FOR 100360.000000 FOR Reata Pharmaceuticals, Inc. 75615P103 US75615P1030 09/21/2023 To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merger Agreement. SECTION 14A SAY-ON-PAY VOTES ISSUER 100360.000000 50400.000000 AGAINST 100360.000000 AGAINST Reata Pharmaceuticals, Inc. 75615P103 US75615P1030 09/21/2023 To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting. CORPORATE GOVERNANCE ISSUER 100360.000000 50400.000000 FOR 100360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 To set the number of Directors at nine. CORPORATE GOVERNANCE ISSUER 201360.000000 0 FOR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Robert V. Baumgartner DIRECTOR ELECTIONS ISSUER 201360.000000 0 AGAINST 201360.000000 AGAINST Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Julie L. Bushman DIRECTOR ELECTIONS ISSUER 201360.000000 0 FOR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: John L. Higgins DIRECTOR ELECTIONS ISSUER 201360.000000 0 AGAINST 201360.000000 AGAINST Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Joseph D. Keegan DIRECTOR ELECTIONS ISSUER 201360.000000 0 FOR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Charles R. Kummeth DIRECTOR ELECTIONS ISSUER 201360.000000 0 FOR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Roeland Nusse DIRECTOR ELECTIONS ISSUER 201360.000000 0 FOR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Alpna Seth DIRECTOR ELECTIONS ISSUER 201360.000000 0 FOR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Randolph Steer DIRECTOR ELECTIONS ISSUER 201360.000000 0 AGAINST 201360.000000 AGAINST Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Election of Directors: Rupert Vessey DIRECTOR ELECTIONS ISSUER 201360.000000 0 FOR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Approve, on an advisory basis, the compensation of our executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 201360.000000 0 AGAINST 201360.000000 AGAINST Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Approve, on an advisory bass, the frequency of advisory votes on executive compensation to occur every (1) year. SECTION 14A SAY-ON-PAY VOTES ISSUER 201360.000000 0 ONE YEAR 201360.000000 FOR Bio-Techne Corporation 09073M104 US09073M1045 10/26/2023 Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2024 fiscal year. AUDIT-RELATED ISSUER 201360.000000 0 FOR 201360.000000 FOR Frequency Therapeutics, Inc. 500946108 US5009461089 11/03/2023 To approve the issuance of shares of common stock of Frequency to stockholders of Korro Bio, Inc., or Korro Bio, pursuant to the terms of the Agreement and Plan of Merger dated as of July 14, 2023, by and among Frequency, Korro Bio, and Frequency Merger Sub, Inc., a direct, wholly owned subsidiary of Frequency, or Merger Sub, a copy of which is attached as Annex A to the accompanying proxy statement/prospectus, pursuant to which Merger Sub will merge with and into Korro Bio, with Korro Bio surviving as a wholly owned subsidiary of Frequency, and the surviving corporation of the merger, or the Merger, and the change of control resulting from the Merger; EXTRAORDINARY TRANSACTIONS ISSUER 231775.000000 0 FOR 231775.000000 FOR Frequency Therapeutics, Inc. 500946108 US5009461089 11/03/2023 To approve an amendment to the Restated Certificate of Incorporation of Frequency, a copy of which is attached as Annex H to the accompanying proxy statement/prospectus, to effect a reverse stock split of Frequency's issued and outstanding common stock at a ratio ranging from any whole number between 1-for-25 and 1-for-50, as determined by the Frequency board of directors in its discretion subject to the Frequency board of directors' authority to abandon such amendment; CAPITAL STRUCTURE ISSUER 231775.000000 0 FOR 231775.000000 FOR Frequency Therapeutics, Inc. 500946108 US5009461089 11/03/2023 To elect David L. Lucchino as a Class I director to hold office until the annual meeting of stockholders to be held in 2026 and until his respective successor has been duly elected and qualified or until his earlier death, resignation or removal; DIRECTOR ELECTIONS ISSUER 231775.000000 0 FOR 231775.000000 FOR Frequency Therapeutics, Inc. 500946108 US5009461089 11/03/2023 To ratify, in a non-binding vote, the appointment of RSM US LLP as Frequency's independent registered public accounting firm for the fiscal year ending December 31, 2023; AUDIT-RELATED ISSUER 231775.000000 0 FOR 231775.000000 FOR Frequency Therapeutics, Inc. 500946108 US5009461089 11/03/2023 To approve the 2023 Stock Option and Incentive Plan a copy of which is attached as Annex I to the accompanying proxy statement/prospectus. COMPENSATION ISSUER 231775.000000 0 AGAINST 231775.000000 AGAINST Frequency Therapeutics, Inc. 500946108 US5009461089 11/03/2023 To approve the 2023 Employee Stock Purchase Plan a copy of which is attached as Annex J to the accompanying proxy statement/prospectus. COMPENSATION ISSUER 231775.000000 0 AGAINST 231775.000000 AGAINST Frequency Therapeutics, Inc. 500946108 US5009461089 11/03/2023 To consider and vote upon an adjournment of the Frequency Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2; CORPORATE GOVERNANCE ISSUER 231775.000000 0 FOR 231775.000000 FOR Abcam Plc 000380204 US0003802040 11/06/2023 Approve Scheme of Arrangement EXTRAORDINARY TRANSACTIONS ISSUER 976460.000000 0 FOR 976460.000000 FOR Abcam Plc 000380204 US0003802040 11/06/2023 Approve Scheme of Arrangement EXTRAORDINARY TRANSACTIONS ISSUER 976460.000000 0 FOR 976460.000000 FOR Abcam Plc 000380204 US0003802040 11/06/2023 Approve Scheme of Arrangement EXTRAORDINARY TRANSACTIONS ISSUER 0.000000 0 Revolution Medicines, Inc. 76155X100 US76155X1000 11/08/2023 To approve the issuance of shares of Revolution Medicines common stock (including securities convertible into or exercisable for shares of Revolution Medicines common stock) to certain equityholders of EQRX, Inc., which is referred to as EQRX, pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (as it may be amended from time to time), by and among Revolution Medicines, Equinox Merger Sub I, Inc., Equinox Merger Sub II LLC, and EQRX, which proposal is referred to as the Revolution Medicines share issuance proposal; and EXTRAORDINARY TRANSACTIONS ISSUER 377632.000000 0 FOR 377632.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 11/08/2023 To approve the adjournment of the Revolution Medicines special meeting, to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Revolution Medicines special meeting to approve the Revolution Medicines share issuance proposal. CORPORATE GOVERNANCE ISSUER 377632.000000 0 FOR 377632.000000 FOR Mirati Therapeutics, Inc. 60468T105 US60468T1051 12/13/2023 To adopt the Agreement and Plan of Merger (the "Merger Agreement"), dated October 8, 2023, by and among Mirati Therapeutics, Inc. ("Mirati"), Bristol-Myers Squibb Company ("Parent") and Vineyard Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the form of contingent value rights agreement to be entered into at or immediately prior to the effective time of the Merger by Parent and a rights agent reasonably acceptable to Mirati, pursuant to which Merger Sub will merge with and into Mirati (the "Merger "), with Mirati surviving the Merger as a wholly owned subsidiary of Parent. EXTRAORDINARY TRANSACTIONS ISSUER 180175.000000 0 FOR 180175.000000 FOR Mirati Therapeutics, Inc. 60468T105 US60468T1051 12/13/2023 To approve, by non-binding, advisory vote, compensation that may be paid or become payable by Mirati to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 180175.000000 0 AGAINST 180175.000000 AGAINST Mirati Therapeutics, Inc. 60468T105 US60468T1051 12/13/2023 To approve the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the special meeting. CORPORATE GOVERNANCE ISSUER 180175.000000 0 FOR 180175.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: William M. Brown DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Catherine M. Burzik DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Carrie L. Byington DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: R. Andrew Eckert DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Claire M. Fraser DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Jeffrey W. Henderson DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Christopher Jones DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Thomas E. Polen DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Timothy M. Ring DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Bertram L. Scott DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Election of Directors: Joanne Waldstreicher DIRECTOR ELECTIONS ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Ratification of the selection of the independent registered public accounting firm. AUDIT-RELATED ISSUER 84050.000000 0 FOR 84050.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/23/2024 Advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 84050.000000 0 FOR 84050.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Michael J. Barber DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Steven K. Barg DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: J. Martin Carroll DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Rolf Classon DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Frank A. D'Amelio DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: John J. Greisch DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Gregory T. Lucier DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Alessandro Maselli DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Donald E. Morel, Jr. DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Stephanie Okey DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Michelle R. Ryan DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Election of Twelve Director Nominees: Jack Stahl DIRECTOR ELECTIONS ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Ratification of Appointment of Ernst & Young LLP as Independent Auditor for Fiscal 2024 AUDIT-RELATED ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Advisory Vote to Approve Our Executive Compensation. (Say-on-Pay). SECTION 14A SAY-ON-PAY VOTES ISSUER 347125.000000 0 FOR 347125.000000 FOR Catalent, Inc. 148806102 US1488061029 01/25/2024 Approval of Amendment to Catalent, Inc. 2018 Omnibus Incentive Plan. COMPENSATION ISSUER 347125.000000 0 FOR 347125.000000 FOR ImmunoGen, Inc. 45253H101 US45253H1014 01/31/2024 A proposal to approve the Agreement and Plan of Merger, dated November 30, 2023 (as may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among ImmunoGen, Inc., a Massachusetts corporation ("ImmunoGen"), AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"). Upon the terms and subject to the conditions of the Merger Agreement, Purchaser will merge with and into ImmunoGen, and the separate corporate existence of Purchaser will thereupon cease, with ImmunoGen continuing as the surviving corporation and as a wholly owned subsidiary of Intermediate Sub in accordance with the Massachusetts Business Corporation Act; EXTRAORDINARY TRANSACTIONS ISSUER 207169.000000 0 FOR 207169.000000 FOR ImmunoGen, Inc. 45253H101 US45253H1014 01/31/2024 A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to ImmunoGen's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement; and SECTION 14A SAY-ON-PAY VOTES ISSUER 207169.000000 0 AGAINST 207169.000000 AGAINST ImmunoGen, Inc. 45253H101 US45253H1014 01/31/2024 A proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the Merger Agreement if there are insufficient votes to approve the Merger Agreement at the time of the Special Meeting. CORPORATE GOVERNANCE ISSUER 207169.000000 0 FOR 207169.000000 FOR Twist Bioscience Corporation 90184D100 US90184D1000 02/06/2024 Election of Class III Directors: Emily M. Leproust, Ph.D. DIRECTOR ELECTIONS ISSUER 130265.000000 0 FOR 130265.000000 FOR Twist Bioscience Corporation 90184D100 US90184D1000 02/06/2024 Election of Class III Directors: Robert Chess DIRECTOR ELECTIONS ISSUER 130265.000000 0 FOR 130265.000000 FOR Twist Bioscience Corporation 90184D100 US90184D1000 02/06/2024 To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Officers, as described in the Proxy Statement under "Executive Compensation." SECTION 14A SAY-ON-PAY VOTES ISSUER 130265.000000 0 FOR 130265.000000 FOR Twist Bioscience Corporation 90184D100 US90184D1000 02/06/2024 Ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2024. AUDIT-RELATED ISSUER 130265.000000 0 FOR 130265.000000 FOR Cerevel Therapeutics Holdings, Inc. 15678U128 US15678U1280 02/16/2024 To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the ''Merger Agreement''), dated as of December 6, 2023, by and among AbbVie Inc., a Delaware corporation (''AbbVie''), Symphony Harlan LLC, a Delaware limited liability company and a wholly owned subsidiary of AbbVie (''Intermediate Holdco''), Symphony Harlan Merger Sub Inc., a Delaware corporation and a direct wholly owned subsidiary of Intermediate Holdco (''Merger Sub''), and Cerevel Therapeutics Holdings, Inc. (''Cerevel''), pursuant to which Merger Sub will be merged with and into Cerevel, with Cerevel surviving as a wholly owned subsidiary of AbbVie (the ''Merger''); EXTRAORDINARY TRANSACTIONS ISSUER 221156.000000 0 FOR 221156.000000 FOR Cerevel Therapeutics Holdings, Inc. 15678U128 US15678U1280 02/16/2024 To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Cerevel's named executive officers that is based on or otherwise relates to the Merger; and SECTION 14A SAY-ON-PAY VOTES ISSUER 221156.000000 0 AGAINST 221156.000000 AGAINST Cerevel Therapeutics Holdings, Inc. 15678U128 US15678U1280 02/16/2024 To approve the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes in person or by proxy to approve the proposal to adopt the Merger Agreement at the time of the special meeting. CORPORATE GOVERNANCE ISSUER 221156.000000 0 FOR 221156.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Stephen P. MacMillan DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Sally W. Crawford DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Charles J. Dockendorff DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Scott T. Garrett DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Ludwig N. Hantson DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Nanaz Mohtashami DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Christiana Stamoulis DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Stacey D. Stewart DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Election of Directors: Amy M. Wendell DIRECTOR ELECTIONS ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 A non-binding advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 4620.000000 0 FOR 4620.000000 FOR Hologic, Inc. 436440101 US4364401012 03/07/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2024. AUDIT-RELATED ISSUER 4620.000000 0 FOR 4620.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Ornella Barra DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Werner Baumann DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Steven H. Collis DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: D. Mark Durcan DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Richard W. Gochnauer DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Lon R. Greenberg DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Kathleen W. Hyle DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Lorence H. Kim, M.D. DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Redonda G. Miller, M.D. DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Dennis M. Nally DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Election of Eleven Directors: Lauren M. Tyler DIRECTOR ELECTIONS ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Advisory vote to approve the compensation of the Company's names executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2024 AUDIT-RELATED ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Approval of an amendment of the certificate of incorporation to provide for the exculpation of officers as permitted by Delaware law. CORPORATE GOVERNANCE ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Approval of miscellaneous amendments to the certificate of incorporation. CORPORATE GOVERNANCE ISSUER 142248.000000 0 FOR 142248.000000 FOR Cencora, Inc. 03073E105 US03073E1055 03/12/2024 Enhance Majority Vote for the Election of Directors CORPORATE GOVERNANCE SECURITY HOLDER 142248.000000 0 AGAINST 142248.000000 FOR Karuna Therapeutics, Inc. 48576A100 US48576A1007 03/12/2024 To adopt the Agreement and Plan of Merger, dated as of December 22, 2023 (the "merger agreement"), among Karuna Therapeutics, Inc. ("Karuna"), Bristol-Myers Squibb Company ("Bristol-Myers Squibb"), and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers Squibb Company ("Merger Sub"), pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will be merged with and into Karuna, and Karuna will survive the merger as a wholly owned subsidiary of Bristol-Myers Squibb. EXTRAORDINARY TRANSACTIONS ISSUER 18250.000000 0 FOR 18250.000000 FOR Karuna Therapeutics, Inc. 48576A100 US48576A1007 03/12/2024 To approve, on an advisory, non-binding basis, certain compensation that will or may be paid by Karuna to its named executive officers that is based on or otherwise relates to the merger of Merger Sub with and into Karuna pursuant to the merger agreement. SECTION 14A SAY-ON-PAY VOTES ISSUER 18250.000000 0 FOR 18250.000000 FOR Karuna Therapeutics, Inc. 48576A100 US48576A1007 03/12/2024 To adjourn the special meeting from time to time, if necessary or appropriate, as determined in good faith by the board of directors of Karuna including for the purpose of soliciting additional votes for the approval of the proposal to adopt the merger agreement if there are insufficient votes at the time of the special meeting to approve the proposal to adopt the merger agreement. CORPORATE GOVERNANCE ISSUER 18250.000000 0 FOR 18250.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Accept Financial Statements and Statutory Reports; Approve Discharge of Management and Board CAPITAL STRUCTURE CORPORATE GOVERNANCE ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Approve Allocation of Income and Omission of Dividends CAPITAL STRUCTURE ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Approve Remuneration Report (Advisory Vote) COMPENSATION ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Reelect Deirdre P. Connelly as Director DIRECTOR ELECTIONS ISSUER 114086.000000 0 ABSTAIN 114086.000000 AGAINST Genmab A/S 372303206 US3723032062 03/13/2024 Reelect Pernille Erenbjerg as Director DIRECTOR ELECTIONS ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Reelect Rolf Hoffmann as Director DIRECTOR ELECTIONS ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Reelect Elizabeth OFarrell as Director DIRECTOR ELECTIONS ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Reelect Paolo Paoletti as Director DIRECTOR ELECTIONS ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Reelect Anders Gersel Pedersen as Director DIRECTOR ELECTIONS ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Ratify Deloitte as Auditors AUDIT-RELATED ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Approve Remuneration of Directors in the Amount of DKK 3 Million for Chairman, DKK 2.4 million for Vice Chairman, and DKK 2.1 million for Other Directors; Approve Remuneration for Committee Work COMPENSATION ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Approve Director Indemnification CORPORATE GOVERNANCE ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Amend Articles Re: Indemnification CORPORATE GOVERNANCE ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Approve Guidelines for Incentive-Based Compensation for Executive Management and Board COMPENSATION ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Approve Creation of DKK 6.6 Million Pool of Capital with Preemptive Rights; Approve Creation of DKK 6.6 Million Pool of Capital without Preemptive Rights CAPITAL STRUCTURE ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Approve Equity Plan Financing Through Issuance of Warrants up to a Nominal Value of DKK 750,000 COMPENSATION ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Authorize Share Repurchase Program CAPITAL STRUCTURE ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S 372303206 US3723032062 03/13/2024 Authorize Editorial Changes to Adopted Resolutions in Connection with Registration with Danish Authorities CORPORATE GOVERNANCE ISSUER 114086.000000 0 FOR 114086.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Accept Financial Statements and Statutory Reports; Approve Discharge of Management and Board CAPITAL STRUCTURE CORPORATE GOVERNANCE ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Approve Allocation of Income and Omission of Dividends CAPITAL STRUCTURE ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Approve Remuneration Report (Advisory Vote) COMPENSATION ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Reelect Deirdre P. Connelly as Director DIRECTOR ELECTIONS ISSUER 34827.000000 0 ABSTAIN 34827.000000 AGAINST Genmab A/S K3967W102 DK0010272202 03/13/2024 Reelect Pernille Erenbjerg as Director DIRECTOR ELECTIONS ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Reelect Rolf Hoffmann as Director DIRECTOR ELECTIONS ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Reelect Elizabeth OFarrell as Director DIRECTOR ELECTIONS ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Reelect Paolo Paoletti as Director DIRECTOR ELECTIONS ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Reelect Anders Gersel Pedersen as Director DIRECTOR ELECTIONS ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Ratify Deloitte as Auditors AUDIT-RELATED ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Approve Remuneration of Directors in the Amount of DKK 3 Million for Chairman, DKK 2.4 million for Vice Chairman, and DKK 2.1 million for Other Directors; Approve Remuneration for Committee Work COMPENSATION ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Approve Director Indemnification CORPORATE GOVERNANCE ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Amend Articles Re: Indemnification CORPORATE GOVERNANCE ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Approve Guidelines for Incentive-Based Compensation for Executive Management and Board COMPENSATION ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Approve Creation of DKK 6.6 Million Pool of Capital with Preemptive Rights; Approve Creation of DKK 6.6 Million Pool of Capital without Preemptive Rights CAPITAL STRUCTURE ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Approve Equity Plan Financing Through Issuance of Warrants up to a Nominal Value of DKK 750,000 COMPENSATION ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Authorize Share Repurchase Program CAPITAL STRUCTURE ISSUER 34827.000000 0 FOR 34827.000000 FOR Genmab A/S K3967W102 DK0010272202 03/13/2024 Authorize Editorial Changes to Adopted Resolutions in Connection with Registration with Danish Authorities CORPORATE GOVERNANCE ISSUER 34827.000000 0 FOR 34827.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Election of Directors: Douglass Given DIRECTOR ELECTIONS ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Election of Directors: Michael S. Perry DIRECTOR ELECTIONS ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Election of Directors: Christopher Anzalone DIRECTOR ELECTIONS ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Election of Directors: Mauro Ferrari DIRECTOR ELECTIONS ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Election of Directors: Adeoye Olukotun DIRECTOR ELECTIONS ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Election of Directors: William Waddill DIRECTOR ELECTIONS ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Election of Directors: Victoria Vakiener DIRECTOR ELECTIONS ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Advisory Vote to Approve Executive Compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 81025.000000 0 FOR 81025.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2024. AUDIT-RELATED ISSUER 81025.000000 0 FOR 81025.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: Colleen E. Jay DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: William A. Kozy DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: Lawrence E. Kurzius DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: Cynthia L. Lucchese DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: Teresa S. Madden DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: Maria Rivas, M.D. DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: Robert S. Weiss DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Elect eight directors to our Board to serve for one-year terms expiring at the 2025 annual meeting of stockholders: Albert G. White III DIRECTOR ELECTIONS ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2024. AUDIT-RELATED ISSUER 99160.000000 0 FOR 99160.000000 FOR The Cooper Companies, Inc. 216648501 US2166485019 03/19/2024 Approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers ("Say on Pay Proposal"). SECTION 14A SAY-ON-PAY VOTES ISSUER 99160.000000 0 FOR 99160.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Approve Treatment of Net Loss CAPITAL STRUCTURE ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Reelect Alf Gunnar Martin Nicklasson as Director DIRECTOR ELECTIONS ISSUER 84280.000000 0 ABSTAIN 84280.000000 AGAINST Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Reelect Kirsten Aarup Drejer as Director DIRECTOR ELECTIONS ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Reelect Jeffrey Berkowitz as Director DIRECTOR ELECTIONS ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Reelect Leonard Kruimer as Director DIRECTOR ELECTIONS ISSUER 84280.000000 0 ABSTAIN 84280.000000 AGAINST Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Reelect Bernadette Mary Connaughton as Director DIRECTOR ELECTIONS ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Elect Elaine Sullivan as New Director DIRECTOR ELECTIONS ISSUER 84280.000000 0 ABSTAIN 84280.000000 AGAINST Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Elect Enrique Conterno as New Director DIRECTOR ELECTIONS ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Ratify Pricewaterhouse Coopers as Auditors AUDIT-RELATED ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Authorize Share Repurchase Program CAPITAL STRUCTURE ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Amend Guidelines for Incentive-Based Compensation for Executive Management and Board COMPENSATION ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Approve Remuneration Report (Advisory Vote) COMPENSATION ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Approve Remuneration of Directors in the Amount of DKK 100,000 for Each Director, and 5,000 RSU for Chair, 1,000 RSU for Vice Chair and 1,500 RSU for Other Directors; Approve Remuneration for Committee Work in RSUs COMPENSATION ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Approve Creation of DKK 12.5 Million Pool of Capital without Preemptive Rights CAPITAL STRUCTURE ISSUER 84280.000000 0 AGAINST 84280.000000 AGAINST Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Approve Issuance of Warrants without Preemptive Rights up to Aggregate Nominal Amount of DKK 767,687 CAPITAL STRUCTURE ISSUER 84280.000000 0 FOR 84280.000000 FOR Zealand Pharma A/S K9898X127 DK0060257814 03/20/2024 Approve Indemnification of Members of the Board of Directors and Executive Management CORPORATE GOVERNANCE ISSUER 84280.000000 0 FOR 84280.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve Allocation of Income and Dividends of DKK 6.40 Per Share CAPITAL STRUCTURE ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve Remuneration Report (Advisory Vote) COMPENSATION ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve Remuneration of Directors in the Amount of DKK 3.4 Million for the Chairman, DKK 1.7 Million for the Vice Chairman and DKK 840,000 for Other Directors; Approve Remuneration for Committee Work COMPENSATION ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve Indemnification of Board of Directors CORPORATE GOVERNANCE ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve Indemnification of Executive Management CORPORATE GOVERNANCE ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Amend Articles Re: Indemnification Scheme CORPORATE GOVERNANCE ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve Guidelines for Incentive-Based Compensation for Executive Management and Board COMPENSATION ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Helge Lund (Chair) as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 ABSTAIN 300335.000000 AGAINST Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Henrik Poulsen (Vice Chair) as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Laurence Debroux as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Andreas Fibig as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Sylvie Gregoire as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Kasim Kutay as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Christina Law as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Reelect Martin Mackay as Director DIRECTOR ELECTIONS ISSUER 300335.000000 0 ABSTAIN 300335.000000 AGAINST Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Ratify Deloitte as Auditor AUDIT-RELATED ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve DKK 4.5 Million Reduction in Share Capital via Share Cancellation of B Shares CAPITAL STRUCTURE ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Authorize Share Repurchase Program CAPITAL STRUCTURE ISSUER 300335.000000 0 FOR 300335.000000 FOR Novo Nordisk A/S K72807140 DK0062498333 03/21/2024 Approve Creation of DKK 44.7 Million Pool of Capital with Preemptive Rights; Approve Creation of DKK 44.7 Million Pool of Capital without Preemptive Rights; Maximum Increase in Share Capital under Both Authorizations up to DKK 44.7 Million CAPITAL STRUCTURE ISSUER 300335.000000 0 FOR 300335.000000 FOR Bio-Rad Laboratories, Inc. 090572207 US0905722072 04/23/2024 Nominees: Melinda Litherland DIRECTOR ELECTIONS ISSUER 20190.000000 0 FOR 20190.000000 FOR Bio-Rad Laboratories, Inc. 090572207 US0905722072 04/23/2024 Nominees: Arnold A. Pinkston DIRECTOR ELECTIONS ISSUER 20190.000000 0 FOR 20190.000000 FOR Bio-Rad Laboratories, Inc. 090572207 US0905722072 04/23/2024 Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors. AUDIT-RELATED ISSUER 20190.000000 0 FOR 20190.000000 FOR Bio-Rad Laboratories, Inc. 090572207 US0905722072 04/23/2024 Approval of the amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan. COMPENSATION ISSUER 20190.000000 0 FOR 20190.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Mark A. Buthman DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: William F. Feehery DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Robert F. Friel DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Eric M. Green DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Thomas W. Hofmann DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Molly E. Joseph DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Deborah L. V. Keller DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Myla P. Lai-Goldman DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Stephen H. Lockhart DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Douglas A. Michels DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Election of Directors: Paolo Pucci DIRECTOR ELECTIONS ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Advisory vote to approve named executive officer compensation; SECTION 14A SAY-ON-PAY VOTES ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Transaction Requirement; CORPORATE GOVERNANCE ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Amendment Requirement; CORPORATE GOVERNANCE ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Ratification of the appointment of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm for 2024; and AUDIT-RELATED ISSUER 35731.000000 0 FOR 35731.000000 FOR West Pharmaceutical Services, Inc. 955306105 US9553061055 04/23/2024 Adopt Simple Majority Vote SHAREHOLDER RIGHTS AND DEFENSES SECURITY HOLDER 35731.000000 0 AGAINST 35731.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 04/25/2024 Election of Class II Directors: Barbara Duncan DIRECTOR ELECTIONS ISSUER 158300.000000 0 FOR 158300.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 04/25/2024 Election of Class II Directors: Mahesh Krishnan DIRECTOR ELECTIONS ISSUER 158300.000000 0 FOR 158300.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 04/25/2024 To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 158300.000000 0 FOR 158300.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 04/25/2024 To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers. CORPORATE GOVERNANCE ISSUER 158300.000000 0 FOR 158300.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 04/25/2024 To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 158300.000000 0 FOR 158300.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Craig H. Barratt, Ph.D. DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Joseph C. Beery DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Lewis Chew DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Gary S. Guthart, Ph.D. DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Amal M. Johnson DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Sreelakshmi Kolli DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Amy L. Ladd, M.D. DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Keith R. Leonard, Jr. DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Jami Dover Nachtsheim DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Monica P. Reed, M.D. DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Election of Directors: Mark J. Rubash DIRECTOR ELECTIONS ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 To approve, by advisory vote, the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 The amendment and restatement of the Amended and Restated 2010 Incentive Award Plan. COMPENSATION ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 The amendment and restatement of the Amended and Restated 2000 Employee Stock Purchase Plan. COMPENSATION ISSUER 19308.000000 0 FOR 19308.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/25/2024 Report on Gender/Racial Pay Gap DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 19308.000000 0 AGAINST 19308.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: R. J. Alpern DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: C. Babineaux-Fontenot DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: S. E. Blount DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: R. B. Ford DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: P. Gonzalez DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: M. A. Kumbier DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: D. W. McDew DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: N. McKinstry DIRECTOR ELECTIONS ISSUER 127770.000000 0 AGAINST 127770.000000 AGAINST Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: M. G. O'Grady DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: M. F. Roman DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: D. J. Starks DIRECTOR ELECTIONS ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Election of 12 Directors: J. G. Stratton DIRECTOR ELECTIONS ISSUER 127770.000000 0 AGAINST 127770.000000 AGAINST Abbott Laboratories 002824100 US0028241000 04/26/2024 Ratification of Ernst & Young LLP As Auditors AUDIT-RELATED ISSUER 127770.000000 0 FOR 127770.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Say on Pay - An Advisory Vote on the Approval of Executive Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 127770.000000 0 FOR 127770.000000 FOR Biohaven Ltd. G1110E107 VGG1110E1079 04/30/2024 Election of Directors for a term expiring at the 2027 Annual Meeting of shareholders: Julia P. Gregory DIRECTOR ELECTIONS ISSUER 99155.000000 0 FOR 99155.000000 FOR Biohaven Ltd. G1110E107 VGG1110E1079 04/30/2024 Election of Directors for a term expiring at the 2027 Annual Meeting of shareholders: John W. Childs DIRECTOR ELECTIONS ISSUER 99155.000000 0 FOR 99155.000000 FOR Biohaven Ltd. G1110E107 VGG1110E1079 04/30/2024 Election of Directors for a term expiring at the 2027 Annual Meeting of shareholders: Gregory H. Bailey, M.D. DIRECTOR ELECTIONS ISSUER 99155.000000 0 FOR 99155.000000 FOR Biohaven Ltd. G1110E107 VGG1110E1079 04/30/2024 Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2024. AUDIT-RELATED ISSUER 99155.000000 0 FOR 99155.000000 FOR Biohaven Ltd. G1110E107 VGG1110E1079 04/30/2024 A non-binding advisory vote on the frequency of future advisory votes on the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 99155.000000 0 ONE YEAR 99155.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Approve Financial Statements and Allocation of Income CAPITAL STRUCTURE CORPORATE GOVERNANCE ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Approve Remuneration Report COMPENSATION ISSUER 74410.000000 0 AGAINST 74410.000000 AGAINST Galapagos NV 36315X101 US36315X1019 04/30/2024 Approve Remuneration Policy COMPENSATION ISSUER 74410.000000 0 AGAINST 74410.000000 AGAINST Galapagos NV 36315X101 US36315X1019 04/30/2024 Approve Discharge of Directors and Auditors AUDIT-RELATED CORPORATE GOVERNANCE ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Approve Remuneration of Directors COMPENSATION ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Reelect Elisabeth Svanberg as Independent Director DIRECTOR ELECTIONS ISSUER 74410.000000 0 AGAINST 74410.000000 AGAINST Galapagos NV 36315X101 US36315X1019 04/30/2024 Elect Susanne Schaffert as Independent Director DIRECTOR ELECTIONS ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Elect Simon Sturge as Independent Director DIRECTOR ELECTIONS ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Elect Andrew Dickinson as Director DIRECTOR ELECTIONS ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Appoint BDO BV, Represented by Ellen Lombaerts, as Auditors In Charge of the Assurance of the CSRD Sustainability Report CORPORATE GOVERNANCE ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Approve Issuance of Subscription Right in the form of a Warrant and Eliminate Preemptive Rights CAPITAL STRUCTURE ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Renew Authorization to Increase Share Capital by Up to 20 Percent within the Framework of Authorized Capital CAPITAL STRUCTURE ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Approve Coordination of Articles of Association CORPORATE GOVERNANCE ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Authorize Board of Directors in Implementation of Approved Resolutions CORPORATE GOVERNANCE ISSUER 74410.000000 0 FOR 74410.000000 FOR Galapagos NV 36315X101 US36315X1019 04/30/2024 Authorize Filing of Required Documents/Formalities at Trade Registry CORPORATE GOVERNANCE ISSUER 74410.000000 0 FOR 74410.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Consolidated Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Allocation of Income and Dividends of EUR 3.76 per Share CAPITAL STRUCTURE ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Reelect Rachel Duan as Director DIRECTOR ELECTIONS ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Reelect Lise Kingo as Director DIRECTOR ELECTIONS ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Elect Clotilde Delbos as Director DIRECTOR ELECTIONS ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Elect Anne-Francoise Nesmes as Director DIRECTOR ELECTIONS ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Elect John Sundy as Director DIRECTOR ELECTIONS ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Compensation Report of Corporate Officers COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Compensation of Serge Weinberg, Chairman of the Board from January 1, 2023 to May 25, 2023 COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Compensation of Frederic Oudea, Chairman of the Board Since May 25, 2023 COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Compensation of Paul Hudson, CEO COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Remuneration Policy of Directors COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Remuneration Policy of Chairman of the Board COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Approve Remuneration Policy of CEO COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Appoint Mazars as Auditor AUDIT-RELATED ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Appoint Mazars as Auditor Responsible for Certifying Sustainability Information CORPORATE GOVERNANCE ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Appoint PricewaterhouseCoopers Audit as Auditor Responsible for Certifying Sustainability Information CORPORATE GOVERNANCE ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Authorize Repurchase of Up to 10 Percent of Issued Share Capital CAPITAL STRUCTURE ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Authorize up to 1.5 Percent of Issued Capital for Use in Restricted Stock Plans COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Authorize Capital Issuances for Use in Employee Stock Purchase Plans COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Reserved for Employees and Corporate Officers of International Subsidiaries COMPENSATION ISSUER 276100.000000 0 FOR 276100.000000 FOR Sanofi 80105N105 US80105N1054 04/30/2024 Authorize Filing of Required Documents/Other Formalities CORPORATE GOVERNANCE ISSUER 276100.000000 0 FOR 276100.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Barbara L. Brasier DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Daniel Cooperman DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Stephen H. Lockhart DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Steven J. Orlando DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Ronna E. Romney DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Richard M. Schapiro DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Dale B. Wolf DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Richard C. Zoretic DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To elect nine directors to hold office until the 2025 Annual Meeting: Joseph M. Zubretsky DIRECTOR ELECTIONS ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To consider and approve, on a non-binding, advisory basis the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 70995.000000 0 FOR 70995.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 05/01/2024 Adopt Simple Majority Vote SHAREHOLDER RIGHTS AND DEFENSES SECURITY HOLDER 70995.000000 0 AGAINST 70995.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: Charles J. Dockendorff DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: Yoshiaki Fujimori DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: Edward J. Ludwig DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: Michael F. Mahoney DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: Jessica L. Mega DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: Susan E. Morano DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: John E. Sununu DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: David S. Wichmann DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 Proposal to elect nine Directors: Ellen M. Zane DIRECTOR ELECTIONS ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 To approve an amendment and restatement of our By-Laws to provide for advance notice and universal proxy rule updates. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 455830.000000 0 FOR 455830.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2024 fiscal year. AUDIT-RELATED ISSUER 455830.000000 0 FOR 455830.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Greg D. Carmichael DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Edward M. Christie III DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Joan E. Herman DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Leslye G. Katz DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Patricia A. Maryland DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Kevin J. O'Connor DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Christopher R. Reidy DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Nancy M. Schlichting DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Mark J. Tarr DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Election of ten nominees to the Board of Directors to serve until our 2025 Annual Meeting of Stockholders: Terrance Williams DIRECTOR ELECTIONS ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 An advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 2323.000000 0 FOR 2323.000000 FOR Encompass Health Corporation 29261A100 US29261A1007 05/02/2024 Report on Effectiveness of the Company's Diversity, Equity, and Inclusion Efforts DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 2323.000000 0 AGAINST 2323.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/02/2024 Election of Class III Directors: Shelley G. Broader DIRECTOR ELECTIONS ISSUER 89190.000000 0 FOR 89190.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/02/2024 Election of Class III Directors: Myriam J. Curet, M.D. DIRECTOR ELECTIONS ISSUER 89190.000000 0 FOR 89190.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/02/2024 Election of Class III Directors: Casey M. Tansey DIRECTOR ELECTIONS ISSUER 89190.000000 0 FOR 89190.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/02/2024 Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 89190.000000 0 FOR 89190.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/02/2024 Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 89190.000000 0 FOR 89190.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Election of Class III Directors: Roxanne S. Austin DIRECTOR ELECTIONS ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Election of Class III Directors: Richard A. Gonzalez DIRECTOR ELECTIONS ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Election of Class III Directors: Susan E. Quaggin DIRECTOR ELECTIONS ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Election of Class III Directors: Rebecca B. Roberts DIRECTOR ELECTIONS ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Election of Class III Directors: Glenn F. Tilton DIRECTOR ELECTIONS ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024 AUDIT-RELATED ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Say on Pay - An advisory vote on the approval of executive compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Say on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 176315.000000 0 ONE YEAR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting CORPORATE GOVERNANCE ISSUER 176315.000000 0 FOR 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Adopt Simple Majority Vote SHAREHOLDER RIGHTS AND DEFENSES SECURITY HOLDER 176315.000000 0 AGAINST 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Report on Lobbying Payments and Policy OTHER SOCIAL ISSUES SECURITY HOLDER 176315.000000 0 AGAINST 176315.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Report on Impact of Extended Patent Exclusivities on Product Access OTHER SOCIAL ISSUES SECURITY HOLDER 176315.000000 0 AGAINST 176315.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Election of the following directors, each to serve a three-year term: Katherine Baicker, Ph.D. DIRECTOR ELECTIONS ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Election of the following directors, each to serve a three-year term: J. Erik Fyrwald DIRECTOR ELECTIONS ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Election of the following directors, each to serve a three-year term: Jamere Jackson DIRECTOR ELECTIONS ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Election of the following directors, each to serve a three-year term: Gabrielle Sulzberger DIRECTOR ELECTIONS ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Approval, on an advisory basis, of the compensation paid to the company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2024. AUDIT-RELATED ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions. CORPORATE GOVERNANCE ISSUER 23825.000000 0 FOR 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Report on Lobbying Payments and Policy OTHER SOCIAL ISSUES SECURITY HOLDER 23825.000000 0 AGAINST 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Report on Effectiveness of Diversity, Equity, and Inclusion Efforts DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 23825.000000 0 AGAINST 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Report on Impact of Extended Patent Exclusivities on Product Access OTHER SOCIAL ISSUES SECURITY HOLDER 23825.000000 0 AGAINST 23825.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Adopt a Comprehensive Human Rights Policy HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE SECURITY HOLDER 23825.000000 0 AGAINST 23825.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Approve Remuneration Report COMPENSATION ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Adopt Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Approve Allocation of Losses to the Retained Earnings of the Company CAPITAL STRUCTURE ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Approve Discharge of Directors CORPORATE GOVERNANCE ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Approve Remuneration Policy COMPENSATION ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Elect Brian L. Kotzin as Non-Executive Director DIRECTOR ELECTIONS ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Reelect Peter Verhaeghe as Non-Executive Director DIRECTOR ELECTIONS ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Reelect Pamela Klein as Non-Executive Director DIRECTOR ELECTIONS ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Grant Board Authority to Issue Shares Up To 10 Percent of Issued Capital and Exclude Pre-emptive Rights CAPITAL STRUCTURE ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Amend Articles of Association and Authorization to Execute the Deed of Amendment CORPORATE GOVERNANCE ISSUER 69167.000000 700.000000 AGAINST 69167.000000 AGAINST argenx SE 04016X101 US04016X1019 05/07/2024 Ratify Deloitte Accountants B.V. as Auditors for the 2024 Financial Year AUDIT-RELATED ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR argenx SE 04016X101 US04016X1019 05/07/2024 Ratify Ernst & Young Accountants LLP as Auditors for the 2025 Financial Year AUDIT-RELATED ISSUER 69167.000000 700.000000 FOR 69167.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Rainer M. Blair DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Feroz Dewan DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Linda Filler DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Teri List DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Jessica L. Mega, MD, MPH DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Mitchell P. Rales DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Steven M. Rales DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Pardis C. Sabeti, MD, D. PHIL DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: A. Shane Sanders DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: John T. Schwieters DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Alan G. Spoon DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Raymond C. Stevens, Ph.D DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2025 Annual Meeting of Shareholders and until their successors are elected and qualified: Elias A. Zerhouni, MD DIRECTOR ELECTIONS ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To approve on an advisory basis the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 82550.000000 0 FOR 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 Reduce Ownership Threshold for Shareholders to Call Special Meeting SHAREHOLDER RIGHTS AND DEFENSES CORPORATE GOVERNANCE SECURITY HOLDER 82550.000000 0 AGAINST 82550.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 Report on Effectiveness of Diversity, Equity, and Inclusion Efforts DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 82550.000000 0 AGAINST 82550.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Leslie C. Davis DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Kieran T. Gallahue DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Leslie S. Heisz DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Paul A. LaViolette DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Steven R. Loranger DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Ramona Sequeira DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Nicholas J. Valeriani DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Election of Directors: Bernard J. Zovighian DIRECTOR ELECTIONS ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Advisory Vote to Approve Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Ratification of Appointment of Independent Registered Public Accounting Firm AUDIT-RELATED ISSUER 171980.000000 0 FOR 171980.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Approval of the Amended and Restated Long-Term Stock Incentive Compensation COMPENSATION ISSUER 171980.000000 0 FOR 171980.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Adoption of Merus N.V.'s Dutch statutory annual accounts in the English language for the financial year 2023, CORPORATE GOVERNANCE ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Appointment of KPMG Accountants N.V. as Merus N.V.'s external auditor for the financial year 2024 for purposes of Dutch law. AUDIT-RELATED ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Release of each member of Merus N.V.'s board of directors from liability for the exercise of their duties during the financial year 2023. CORPORATE GOVERNANCE ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Re-appointment of Mark Iwicki as non-executive director. DIRECTOR ELECTIONS ISSUER 384472.000000 0 AGAINST 384472.000000 AGAINST Merus N.V. N5749R100 NL0011606264 05/07/2024 Re-appointment of Paolo Pucci as non-executive director. DIRECTOR ELECTIONS ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Appointment of Jason Haddock as non-executive director. DIRECTOR ELECTIONS ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Articles Amendment A - Approval of the amendment of the Articles of Association to increase the authorized share capital to the amount of EUR 18,900,000 and divided into 105,000,000 common shares and 105,000,000 preferred shares and authorization to implement such amendment. CAPITAL STRUCTURE ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Articles Amendment B - Approval of the amendment of the Articles of Association to reflect the Large Company Regime and authorization to implement such amendment. CORPORATE GOVERNANCE ISSUER 384472.000000 0 AGAINST 384472.000000 AGAINST Merus N.V. N5749R100 NL0011606264 05/07/2024 Granting authorization to Menus N.V.'s board of directors to acquire shares (or depository receipts for such shares) in Merus N.V.'s capital. CAPITAL STRUCTURE ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 384472.000000 0 FOR 384472.000000 FOR Merus N.V. N5749R100 NL0011606264 05/07/2024 Approval of the amendment of the Merus N.V.'s Non- Executive Director Compensation Program ("NED Program") to allow the board of directors to determine the number of common shares that may be awarded to a non-executive director for initial and annual awards under the NED Program to more closely align with the 50th percentile of the Company's peer group. COMPENSATION ISSUER 384472.000000 0 AGAINST 384472.000000 AGAINST Merus N.V. N5749R100 NL0011606264 05/07/2024 Approval of the amendment and restatement of the Merus NV. 2016 Incentive Award Plan (the "2016 Plan"), to extend the term of the 2016 Plan to December 31, 2031, which includes a corresponding extension to the annual "evergreen" feature from and including January 1, 2026, to January 1, 2029, along with other minor amendments updated for best practices. COMPENSATION ISSUER 384472.000000 0 AGAINST 384472.000000 AGAINST Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: James C. Foster DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Nancy C. Andrews DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Robert Bertolini DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Reshema Kemps-Polanco DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Deborah T. Kochevar DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: George Llado, Sr. DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Martin W. Mackay DIRECTOR ELECTIONS ISSUER 102105.000000 0 AGAINST 102105.000000 AGAINST Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: George E. Massaro DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Craig B. Thompson DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Richard F. Wallman DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Election of Directors: Virginia M. Wilson DIRECTOR ELECTIONS ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Advisory Approval of 2023 Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Ratification of PricewaterhouseCoopers LLC as independent registered public accounting firm for 2024 AUDIT-RELATED ISSUER 102105.000000 0 FOR 102105.000000 FOR Charles River Laboratories International, Inc. 159864107 US1598641074 05/08/2024 Report on Imported Nonhuman Primates OTHER SOCIAL ISSUES SECURITY HOLDER 102105.000000 0 AGAINST 102105.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Approve Non-Financial Report CORPORATE GOVERNANCE ENVIRONMENT OR CLIMATE HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE DIVERSITY, EQUITY, AND INCLUSION OTHER SOCIAL ISSUES ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Approve Remuneration Report COMPENSATION ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Approve Discharge of Board and Senior Management CORPORATE GOVERNANCE ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Approve Allocation of Income and Dividends of CHF 4.00 per Share CAPITAL STRUCTURE ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reelect Marion Helmes as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reelect Angelica Kohlmann as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reelect Christoph Maeder as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reelect Roger Nitsch as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reelect Barbara Richmond as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reelect Juergen Steinemann as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reelect Olivier Verscheure as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Elect Jean-Marc Huet as Director DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Elect Jean-Marc Huet as Board Chair DIRECTOR ELECTIONS ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reappoint Angelica Kohlmann as Member of the Nomination and Compensation Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reappoint Christoph Maeder as Member of the Nomination and Compensation Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Reappoint Juergen Steinemann as Member of the Nomination and Compensation Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Ratify Deloitte AG as Auditors for Fiscal Year 2025 AUDIT-RELATED ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Designate ThomannFischer as Independent Proxy CORPORATE GOVERNANCE ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Approve Remuneration of Directors in the Amount of CHF 3 Million COMPENSATION ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Approve Variable Short-Term Remuneration of Executive Committee in the Amount of CHF 4.3 Million COMPENSATION ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Approve Fixed and Variable Long-Term Remuneration of Executive Committee in the Amount of CHF 27.7 Million COMPENSATION ISSUER 23365.000000 0 FOR 23365.000000 FOR Lonza Group AG H50524133 CH0013841017 05/08/2024 Transact Other Business (Voting) CORPORATE GOVERNANCE ISSUER 23365.000000 0 ABSTAIN 23365.000000 AGAINST Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Roland Diggelmann DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Domitille Doat-Le Bigot DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Elisha W. Finney DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Richard Francis DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Michael A. Kelly DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Thomas P. Salice DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Wolfgang Wienand DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ELECTION OF DIRECTORS: Ingrid Zhang DIRECTOR ELECTIONS ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AUDIT-RELATED ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Mettler-Toledo International Inc. 592688105 US5926881054 05/09/2024 ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION SECTION 14A SAY-ON-PAY VOTES ISSUER 14790.000000 800.000000 FOR 14790.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Mary K. Brainerd DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Giovanni Caforio, M.D. DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Allan C. Golston DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Kevin A. Lobo DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Sherilyn S. McCoy DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Rachel Ruggeri DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Andrew K. Silvernail DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Lisa M. Skeete Tatum DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Ronda E. Stryker DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Election of Ten Directors: Rajeev Suri DIRECTOR ELECTIONS ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2024. AUDIT-RELATED ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Advisory Vote to Approve Named Executive Officer Compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 70805.000000 0 FOR 70805.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Report on Political Contributions and Expenditures OTHER SOCIAL ISSUES SECURITY HOLDER 70805.000000 0 AGAINST 70805.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Christopher B. Begley DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Betsy J. Bernard DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Michael J. Farrell DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Robert A. Hagemann DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Arthur J. Higgins DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Maria Teresa Hilado DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Syed Jafry DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Sreelakshmi Kolli DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Louis Shapiro DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Election of Directors: Ivan Tornos DIRECTOR ELECTIONS ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Approve, on a non-binding advisory basis, named executive officer compensation ("Say on Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 79195.000000 0 FOR 79195.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Approve the amended Employee Stock Purchase Plan. COMPENSATION ISSUER 79195.000000 0 FOR 79195.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: David R. Brennan DIRECTOR ELECTIONS ISSUER 166575.000000 0 FOR 166575.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Leo Lee DIRECTOR ELECTIONS ISSUER 166575.000000 0 FOR 166575.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Carol A. Schafer DIRECTOR ELECTIONS ISSUER 166575.000000 0 FOR 166575.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Melvin Sharoky, M.D. DIRECTOR ELECTIONS ISSUER 166575.000000 0 FOR 166575.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 An advisory vote on the 2023 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 166575.000000 0 FOR 166575.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 166575.000000 0 FOR 166575.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. COMPENSATION ISSUER 166575.000000 0 FOR 166575.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Jessica L. Blume DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Kenneth A. Burdick DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Christopher J. Coughlin DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: H. James Dallas DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Wayne S. DeVeydt DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Frederick H. Eppinger DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Monte E. Ford DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Sarah M. London DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Lori J. Robinson DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ELECTION OF DIRECTORS: Theodore R. Samuels DIRECTOR ELECTIONS ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2024. AUDIT-RELATED ISSUER 179980.000000 0 FOR 179980.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 Adopt Near and Long-Term Science-Based GHG Emissions Reduction Targets Aligned with Paris Agreement Goal ENVIRONMENT OR CLIMATE SECURITY HOLDER 179980.000000 0 AGAINST 179980.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/15/2024 Election of Directors: Lewis Hay, III DIRECTOR ELECTIONS ISSUER 31965.000000 0 FOR 31965.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/15/2024 Election of Directors: Antonio F. Neri DIRECTOR ELECTIONS ISSUER 31965.000000 0 FOR 31965.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/15/2024 Election of Directors: Ramiro G. Peru DIRECTOR ELECTIONS ISSUER 31965.000000 0 FOR 31965.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/15/2024 Advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 31965.000000 0 FOR 31965.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/15/2024 To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 31965.000000 0 FOR 31965.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/15/2024 Adopt a Policy Requiring Third Party Groups to Report Their Political Expenditures OTHER SOCIAL ISSUES SECURITY HOLDER 31965.000000 0 AGAINST 31965.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Sangeeta Bhatia DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Lloyd Carney DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Alan Garber DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Reshma Kewalramani DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Michel Lagarde DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Jeffrey Leiden DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Diana McKenzie DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Bruce Sachs DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Jennifer Schneider DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Nancy Thornberry DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Election of Directors: Suketu Upadhyay DIRECTOR ELECTIONS ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Advisory vote to approve named executive office compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 20125.000000 0 FOR 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Reduce Ownership Threshold for Shareholders to Call Special Meeting SHAREHOLDER RIGHTS AND DEFENSES CORPORATE GOVERNANCE SECURITY HOLDER 20125.000000 0 AGAINST 20125.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Report on Median and Adjusted Gender/Racial Pay Gaps DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 20125.000000 0 AGAINST 20125.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/16/2024 To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D. DIRECTOR ELECTIONS ISSUER 109667.000000 0 FOR 109667.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/16/2024 To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D. DIRECTOR ELECTIONS ISSUER 109667.000000 0 FOR 109667.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/16/2024 To elect the following nominees as Class II directors of Alnylam: Peter N. Kellogg DIRECTOR ELECTIONS ISSUER 109667.000000 0 FOR 109667.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/16/2024 To elect the following nominees as Class II directors of Alnylam: David E.I. Pyott DIRECTOR ELECTIONS ISSUER 109667.000000 0 FOR 109667.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/16/2024 To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 109667.000000 0 FOR 109667.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/16/2024 To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 109667.000000 0 FOR 109667.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 Ordinary Resolutions To re-elect as a director Kevin Lee, who retires in accordance with the Articles of Association DIRECTOR ELECTIONS ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To re-elect as a director Jose-Carlos Gutierrez-Ramos, who retires in accordance with the Articles of Association DIRECTOR ELECTIONS ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2024 AUDIT-RELATED ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders AUDIT-RELATED ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To authorize the Audit Committee to determine our U.K. statutory 31,2024 auditors' remuneration for the year ending December 31, 2024 AUDIT-RELATED ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2023 (the "2023 U.K. Annual Report") CORPORATE GOVERNANCE ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To approve our directors' remuneration report for the year ended December 31, 2023 (the "directors' remuneration report"), which is set forth as Annex A to the proxy statement COMPENSATION ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To authorize the Board of Directors to allot shares or to grant rights to subscribe for or convert any security into shares up to a maximum aggregate nominal amount of pounds1,000,000 CAPITAL STRUCTURE ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 Special Resolutions To empower the Board of Directors to allot equity securities for cash up to a maximum aggregate nominal amount of pounds1,000,000 pursuant to the authorization in Resolution 9 as if U.K. statutory pre-emption rights did not apply CAPITAL STRUCTURE ISSUER 278270.000000 0 FOR 278270.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To adopt new articles of association, which are set forth in Annex B to the proxy statement CORPORATE GOVERNANCE ISSUER 278270.000000 0 FOR 278270.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Approve Remuneration Report COMPENSATION ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Approve Final Dividend CAPITAL STRUCTURE ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect John McAdam as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Karim Bitar as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Jonny Mason as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Margaret Ewing as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Brian May as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Constantin Coussios as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Heather Mason as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Kim Lody as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Re-elect Sharon O'Keefe as Director DIRECTOR ELECTIONS ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Reappoint Deloitte LLP as Auditors AUDIT-RELATED ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Authorise Board to Fix Remuneration of Auditors AUDIT-RELATED ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Approve Amendments to the Long Term Incentive Plan 2016 COMPENSATION ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Authorise UK Political Donations and Expenditure OTHER SOCIAL ISSUES ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Authorise Issue of Equity CAPITAL STRUCTURE ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Authorise Issue of Equity without Pre-emptive Rights CAPITAL STRUCTURE ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment CAPITAL STRUCTURE ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Authorise Market Purchase of Ordinary Shares CAPITAL STRUCTURE ISSUER 4411215.000000 0 FOR 4411215.000000 FOR ConvaTec Group Plc G23969101 GB00BD3VFW73 05/16/2024 Authorise the Company to Call General Meeting with Two Weeks' Notice CORPORATE GOVERNANCE ISSUER 4411215.000000 0 FOR 4411215.000000 FOR Pulmonx Corporation 745848101 US7458481014 05/16/2024 Election of Directors: Glendon E. French DIRECTOR ELECTIONS ISSUER 335566.000000 0 FOR 335566.000000 FOR Pulmonx Corporation 745848101 US7458481014 05/16/2024 Election of Directors: Tiffany Sullivan DIRECTOR ELECTIONS ISSUER 335566.000000 0 FOR 335566.000000 FOR Pulmonx Corporation 745848101 US7458481014 05/16/2024 To ratify the selection by the Audit Committee of our Board of Directors of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 335566.000000 0 FOR 335566.000000 FOR Pulmonx Corporation 745848101 US7458481014 05/16/2024 To conduct a non-binding advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 335566.000000 0 FOR 335566.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Tony J. Hunt DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Karen A. Dawes DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Nicolas M. Barthelemy DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Carrie Eglinton Manner DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Konstantin Konstantinov, Ph.D. DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Martin D. Madaus, D.V.M., Ph.D. DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Rohin Mhatre, Ph.D. DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Glenn P. Muir DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Election of Directors: Margaret A. Pax DIRECTOR ELECTIONS ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Ratification of the selection of Ernst & Young LLP as Repligen Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 95255.000000 0 FOR 95255.000000 FOR Repligen Corporation 759916109 US7599161095 05/16/2024 Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 95255.000000 0 FOR 95255.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Kevin J. McNamara DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Ron DeLyons DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Patrick P. Grace DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Christopher J. Heaney DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Thomas C. Hutton DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Andrea R. Lindell DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Eileen P. McCarthy DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: John M. Mount, Jr. DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: Thomas P. Rice DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Election of directors: George J. Walsh III DIRECTOR ELECTIONS ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Ratification of Audit Committee's selection of PricewaterhouseCoopers LLP as independent accountants for 2024. AUDIT-RELATED ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 10662.000000 0 FOR 10662.000000 FOR Chemed Corporation 16359R103 US16359R1032 05/20/2024 Submit Severance Agreement (Change-in-Control) to Shareholder Vote COMPENSATION SECURITY HOLDER 10662.000000 0 AGAINST 10662.000000 FOR 4D Molecular Therapeutics, Inc. 35104E100 US35104E1001 05/21/2024 Election of one Class I director to hold office until the 2027 Annual Meeting of Stockholders or until their successor is elected: David Kirn, M.D. DIRECTOR ELECTIONS ISSUER 116138.000000 30300.000000 FOR 116138.000000 FOR 4D Molecular Therapeutics, Inc. 35104E100 US35104E1001 05/21/2024 Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 116138.000000 30300.000000 FOR 116138.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Elizabeth M. Anderson DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Barbara W. Bodem DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Athena Countouriotis DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Willard Dere DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Mark J. Enyedy DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Alexander Hardy DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Elaine J. Heron DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Maykin Ho DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Robert J. Hombach DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: Richard A. Meier DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 Election of Directors: David E.I. Pyott DIRECTOR ELECTIONS ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 397312.000000 0 FOR 397312.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 397312.000000 0 FOR 397312.000000 FOR MacroGenics, Inc. 556099109 US5560991094 05/21/2024 To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: Scott Jackson DIRECTOR ELECTIONS ISSUER 190555.000000 0 FOR 190555.000000 FOR MacroGenics, Inc. 556099109 US5560991094 05/21/2024 To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: Margaret Liu, M.D. DIRECTOR ELECTIONS ISSUER 190555.000000 0 FOR 190555.000000 FOR MacroGenics, Inc. 556099109 US5560991094 05/21/2024 To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: David Stump, M.D. DIRECTOR ELECTIONS ISSUER 190555.000000 0 FOR 190555.000000 FOR MacroGenics, Inc. 556099109 US5560991094 05/21/2024 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 190555.000000 0 FOR 190555.000000 FOR MacroGenics, Inc. 556099109 US5560991094 05/21/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials. SECTION 14A SAY-ON-PAY VOTES ISSUER 190555.000000 0 FOR 190555.000000 FOR MacroGenics, Inc. 556099109 US5560991094 05/21/2024 To approve the amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan, as disclosed in the proxy materials. COMPENSATION ISSUER 190555.000000 0 FOR 190555.000000 FOR Viking Therapeutics, Inc. 92686J106 US92686J1060 05/21/2024 ELECTION OF DIRECTORS FOR CLASS III (term to expire in 2027): Brian Lian, Ph.D. DIRECTOR ELECTIONS ISSUER 190020.000000 0 FOR 190020.000000 FOR Viking Therapeutics, Inc. 92686J106 US92686J1060 05/21/2024 ELECTION OF DIRECTORS FOR CLASS III (term to expire in 2027): Lawson Macartney, DVM, Ph.D. DIRECTOR ELECTIONS ISSUER 190020.000000 0 WITHHOLD 190020.000000 AGAINST Viking Therapeutics, Inc. 92686J106 US92686J1060 05/21/2024 RATIFICATION OF THE SELECTION OF MARCUM LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024. AUDIT-RELATED ISSUER 190020.000000 0 FOR 190020.000000 FOR Viking Therapeutics, Inc. 92686J106 US92686J1060 05/21/2024 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 190020.000000 0 FOR 190020.000000 FOR Viking Therapeutics, Inc. 92686J106 US92686J1060 05/21/2024 TO APPROVE OUR 2024 EQUITY INCENTIVE PLAN. COMPENSATION ISSUER 190020.000000 0 FOR 190020.000000 FOR Viking Therapeutics, Inc. 92686J106 US92686J1060 05/21/2024 TO APPROVE OUR 2024 EMPLOYEE STOCK PURCHASE PLAN. COMPENSATION ISSUER 190020.000000 0 FOR 190020.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Kevin T. Conroy DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Kevin J. Dallas DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Joseph M. Hogan DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Joseph Lacob DIRECTOR ELECTIONS ISSUER 128860.000000 0 AGAINST 128860.000000 AGAINST Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: C. Raymond Larkin, Jr DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: George J. Morrow DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Anne M. Myong DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Mojdeh Poul DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Andrea L. Saia DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Election of Directors: Susan E. Siegel DIRECTOR ELECTIONS ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS: Proposal to ratify the appointment of PricewaterhouseCoopers LLP as Align Technology, Inc.'s independent registered public accountants for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 ADVISORY VOTE ON NAMED EXECUTIVES' COMPENSATION Consider an Advisory Vote to Approve the Compensation of our Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 128860.000000 0 FOR 128860.000000 FOR Align Technology, Inc. 016255101 US0162551016 05/22/2024 Adopt Simple Majority Vote SHAREHOLDER RIGHTS AND DEFENSES SECURITY HOLDER 128860.000000 0 FOR 128860.000000 AGAINST CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: David Bronson DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: Brian P. Concannon DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: LaVerne Council DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: Charles M. Farkas DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: Martha Goldberg Aronson DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: Curt R. Hartman DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: Barbara J. Schwarzentraub DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To elect eight directors to serve on the Company's Board of Directors: John L. Workman DIRECTOR ELECTIONS ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 Advisory Vote on Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 98215.000000 0 FOR 98215.000000 FOR CONMED Corporation 207410101 US2074101013 05/22/2024 To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; AUDIT-RELATED ISSUER 98215.000000 0 FOR 98215.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Kevin R. Sayer DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Steven R. Altman DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Nicholas Augustinos DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Richard A. Collins DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Karen Dahut DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Rimma Driscoll DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Mark G. Foletta DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Bridgette P. Heller DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Kyle Malady DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders: Eric J. Topol, M.D. DIRECTOR ELECTIONS ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2023. SECTION 14A SAY-ON-PAY VOTES ISSUER 115155.000000 0 FOR 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 Report on Median Gender/Racial Pay Gap DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 115155.000000 0 AGAINST 115155.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 Report on Political Contributions OTHER SOCIAL ISSUES SECURITY HOLDER 115155.000000 0 AGAINST 115155.000000 FOR Dyne Therapeutics, Inc. 26818M108 US26818M1080 05/22/2024 The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Carlo Incerti, M.D. DIRECTOR ELECTIONS ISSUER 148946.000000 0 FOR 148946.000000 FOR Dyne Therapeutics, Inc. 26818M108 US26818M1080 05/22/2024 The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Catherine Stehman-Breen, M.D. DIRECTOR ELECTIONS ISSUER 148946.000000 0 FOR 148946.000000 FOR Dyne Therapeutics, Inc. 26818M108 US26818M1080 05/22/2024 The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: John G. Cox DIRECTOR ELECTIONS ISSUER 148946.000000 0 FOR 148946.000000 FOR Dyne Therapeutics, Inc. 26818M108 US26818M1080 05/22/2024 The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 148946.000000 0 FOR 148946.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 Election of Directors: William H. Rastetter, Ph.D. DIRECTOR ELECTIONS ISSUER 204955.000000 0 FOR 204955.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 Election of Directors: George J. Morrow DIRECTOR ELECTIONS ISSUER 204955.000000 0 FOR 204955.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 Election of Directors: Leslie V. Norwalk DIRECTOR ELECTIONS ISSUER 204955.000000 0 FOR 204955.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 Election of Directors: Christine A. Poon DIRECTOR ELECTIONS ISSUER 204955.000000 0 FOR 204955.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 Advisory vote on the compensation paid to the Company's named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 204955.000000 0 FOR 204955.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 To approve an amendment of the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 3,635,000 shares; and COMPENSATION ISSUER 204955.000000 0 FOR 204955.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 204955.000000 0 FOR 204955.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Rebecca Robertson DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Dick Allen DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Myoungil Cha DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Peyton Howell DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Joao Malagueira DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Kathleen McGroddy-Goetz DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: John Sheridan DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Rajwant Sodhi DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders: Christopher Twomey DIRECTOR ELECTIONS ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To approve the Company's 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares authorized for issuance under the plan. COMPENSATION ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To approve the Company's 2023 Long-Term Incentive Plan, as amended, to increase the number of shares authorized for issuance under the plan. COMPENSATION ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 129700.000000 0 FOR 129700.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/22/2024 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 129700.000000 0 FOR 129700.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To re-appoint as a director Bahija Jallal, Ph.D., who retires in accordance with the articles of association. DIRECTOR ELECTIONS ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To re-appoint as a director Professor Sir John Bell, who retires in accordance with the articles of association. DIRECTOR ELECTIONS ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 53268.000000 6600.000000 ONE YEAR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. AUDIT-RELATED ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To authorize the directors to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2024. AUDIT-RELATED ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To receive and adopt the U.K. statutory annual accounts and reports for the year ended December 31, 2023 (the "2023 U.K. Annual Report"). CORPORATE GOVERNANCE ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To approve the directors' remuneration report for the year ended December 31, 2023, which is set forth as Annex A to the proxy statement and on pages 20 to 47 (inclusive) of the 2023 U.K. Annual Report. COMPENSATION ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 To authorise the Company to make political donations/ incur political expenditure. OTHER SOCIAL ISSUES ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Immunocore Holdings Plc 45258D105 US45258D1054 05/23/2024 That, with effect from the conclusion of the AGM, the draft articles of association produced to the AGM and, for the purpose of identification, initialed by the Chairman, be adopted as the articles of association of the Company in substitution for, and to the exclusion of, the Company's existing articles of association. CORPORATE GOVERNANCE ISSUER 53268.000000 6600.000000 FOR 53268.000000 FOR Longboard Pharmaceuticals, Inc. 54300N103 US54300N1037 05/23/2024 To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Paul J. Sekhri DIRECTOR ELECTIONS ISSUER 28227.000000 0 WITHHOLD 28227.000000 AGAINST Longboard Pharmaceuticals, Inc. 54300N103 US54300N1037 05/23/2024 To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Phillip M. Schneider DIRECTOR ELECTIONS ISSUER 28227.000000 0 FOR 28227.000000 FOR Longboard Pharmaceuticals, Inc. 54300N103 US54300N1037 05/23/2024 To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the Delaware General Corporation Law. CORPORATE GOVERNANCE ISSUER 28227.000000 0 FOR 28227.000000 FOR Longboard Pharmaceuticals, Inc. 54300N103 US54300N1037 05/23/2024 To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 28227.000000 0 FOR 28227.000000 FOR Rapid Micro Biosystems, Inc. 75340L104 US75340L1044 05/23/2024 To elect three Class III Directors to serve until the 2027 Annual Meeting of Stockholders: Kirk D. Malloy, Ph.D. DIRECTOR ELECTIONS ISSUER 549778.000000 0 FOR 549778.000000 FOR Rapid Micro Biosystems, Inc. 75340L104 US75340L1044 05/23/2024 To elect three Class III Directors to serve until the 2027 Annual Meeting of Stockholders: Melinda Litherland DIRECTOR ELECTIONS ISSUER 549778.000000 0 FOR 549778.000000 FOR Rapid Micro Biosystems, Inc. 75340L104 US75340L1044 05/23/2024 To elect three Class III Directors to serve until the 2027 Annual Meeting of Stockholders: Robert Spignesi DIRECTOR ELECTIONS ISSUER 549778.000000 0 FOR 549778.000000 FOR Rapid Micro Biosystems, Inc. 75340L104 US75340L1044 05/23/2024 To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 549778.000000 0 FOR 549778.000000 FOR Rapid Micro Biosystems, Inc. 75340L104 US75340L1044 05/23/2024 To approve an amendment to our Restated Certificate of Incorporation to reflect new Delaware law provisions allowing for officer exculpation. CORPORATE GOVERNANCE ISSUER 549778.000000 0 FOR 549778.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Dr. Flemming Ornskov, M.D., M.P.H. DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Linda Baddour DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Udit Batra, Ph.D. DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Dan Brennan DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Richard Fearon DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Pearl S. Huang, Ph.D. DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Wei Jiang DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Christopher A. Kuebler DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To elect directors to serve for the ensuing year and until their successors are elected: Mark Vergnano DIRECTOR ELECTIONS ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; AUDIT-RELATED ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To approve, by non-binding vote, executive compensation; SECTION 14A SAY-ON-PAY VOTES ISSUER 90145.000000 0 FOR 90145.000000 FOR Waters Corporation 941848103 US9418481035 05/23/2024 To amend the Company's certificate of incorporation to provide for exculpation of certain officers of the Company as permitted by recent amendments to Delaware law; and CORPORATE GOVERNANCE ISSUER 90145.000000 0 FOR 90145.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Douglas M. Baker, Jr. DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Mary Ellen Coe DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Pamela J. Craig DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Robert M. Davis DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Thomas H. Glocer DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Risa J. Lavizzo-Mourey, M.D. DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Stephen L. Mayo, Ph.D. DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Paul B. Rothman, M.D. DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Patricia F. Russo DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Christine E. Seidman, M.D. DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Inge G. Thulin DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Election of Directors: Kathy J. Warden DIRECTOR ELECTIONS ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Non-binding advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Ratification of the appointment of the Company's independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 200730.000000 0 FOR 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Provide Right to Act by Written Consent SHAREHOLDER RIGHTS AND DEFENSES SECURITY HOLDER 200730.000000 0 AGAINST 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Disclose a Government Censorship Transparency Report OTHER SOCIAL ISSUES SECURITY HOLDER 200730.000000 0 AGAINST 200730.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Report on Civil Rights and Non-Discrimination Audit HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 200730.000000 0 AGAINST 200730.000000 FOR Arvinas, Inc. 04335A105 US04335A1051 05/29/2024 Election of Directors: Edward Kennedy, Jr. DIRECTOR ELECTIONS ISSUER 232960.000000 0 FOR 232960.000000 FOR Arvinas, Inc. 04335A105 US04335A1051 05/29/2024 Election of Directors: Everett Cunningham DIRECTOR ELECTIONS ISSUER 232960.000000 0 FOR 232960.000000 FOR Arvinas, Inc. 04335A105 US04335A1051 05/29/2024 Election of Directors: Briggs Morrison, M.D. DIRECTOR ELECTIONS ISSUER 232960.000000 0 WITHHOLD 232960.000000 AGAINST Arvinas, Inc. 04335A105 US04335A1051 05/29/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 232960.000000 0 FOR 232960.000000 FOR Arvinas, Inc. 04335A105 US04335A1051 05/29/2024 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 232960.000000 0 FOR 232960.000000 FOR Catalent, Inc. 148806102 US1488061029 05/29/2024 To adopt and approve the Agreement and Plan of Merger, dated as of February 5, 2024, by and among Catalent, Creek Parent, Inc., and Creek Merger Sub, Inc. (the "Merger" and "Merger Proposal"); EXTRAORDINARY TRANSACTIONS ISSUER 173410.000000 0 FOR 173410.000000 FOR Catalent, Inc. 148806102 US1488061029 05/29/2024 To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Catalent's named executive officers that is based on or otherwise relates to the Merger; and SECTION 14A SAY-ON-PAY VOTES ISSUER 173410.000000 0 FOR 173410.000000 FOR Catalent, Inc. 148806102 US1488061029 05/29/2024 To approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if a quorum is not present or there are not sufficient votes cast at the Special Meeting to approve the Merger Proposal. CORPORATE GOVERNANCE ISSUER 173410.000000 0 FOR 173410.000000 FOR Shockwave Medical, Inc. 82489T104 US82489T1043 05/29/2024 To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated April 4, 2024, by and among Shockwave Medical, Inc., a Delaware corporation ("Shockwave"), Johnson & Johnson, a New Jersey corporation ("Johnson & Johnson"), and Sweep Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson ("Merger Sub"), pursuant to which the Merger Sub will merge with and into Shockwave (the "Merger"), with Shockwave surviving the Merger as a wholly owned subsidiary of Johnson & Johnson. EXTRAORDINARY TRANSACTIONS ISSUER 63915.000000 0 FOR 63915.000000 FOR Shockwave Medical, Inc. 82489T104 US82489T1043 05/29/2024 To approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Shockwave's named executive officers that is based on or otherwise relates to the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 63915.000000 0 AGAINST 63915.000000 AGAINST Shockwave Medical, Inc. 82489T104 US82489T1043 05/29/2024 To adjourn the Special Meeting of Stockholders to a later date or dates as provided in the Merger Agreement, if necessary or appropriate, including to solicit additional votes if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting of Stockholders. CORPORATE GOVERNANCE ISSUER 63915.000000 0 FOR 63915.000000 FOR Bruker Corporation 116794108 US1167941087 05/30/2024 Election of three Class III directors to serve for a three-year term expiring in 2027: William A. Linton DIRECTOR ELECTIONS ISSUER 185257.000000 0 FOR 185257.000000 FOR Bruker Corporation 116794108 US1167941087 05/30/2024 Election of three Class III directors to serve for a three-year term expiring in 2027: Adelene Q. Perkins DIRECTOR ELECTIONS ISSUER 185257.000000 0 FOR 185257.000000 FOR Bruker Corporation 116794108 US1167941087 05/30/2024 Election of three Class III directors to serve for a three-year term expiring in 2027: Robert J. Rosenthal DIRECTOR ELECTIONS ISSUER 185257.000000 0 FOR 185257.000000 FOR Bruker Corporation 116794108 US1167941087 05/30/2024 Approval on an advisory basis of the 2023 compensation of our named executive officers, as discussed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 185257.000000 0 FOR 185257.000000 FOR Bruker Corporation 116794108 US1167941087 05/30/2024 Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 185257.000000 0 FOR 185257.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Election of Directors: William Doyle DIRECTOR ELECTIONS ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Election of Directors: Art Garcia DIRECTOR ELECTIONS ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Election of Directors: Denise Scots-Knight DIRECTOR ELECTIONS ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Election of Directors: Jeffrey Simmons DIRECTOR ELECTIONS ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Advisory vote on the compensation of company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Approval of the amendment of the Articles of Incorporation to declassify the Board of Directors. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Approval of the amendment of the Articles of Incorporation to adopt a majority vote standard for uncontested elections of Directors. CORPORATE GOVERNANCE ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Approval of the amendment of the Articles of Incorporation to provide shareholders with the right to amend the company's Bylaws. CORPORATE GOVERNANCE ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Elanco Animal Health Incorporated 28414H103 US28414H1032 05/30/2024 Approval of the amendment of the Articles of Incorporation to provide shareholders with the right to request special meetings of shareholders. CORPORATE GOVERNANCE ISSUER 1234695.000000 0 FOR 1234695.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Mary C. Beckerle, Ph.D. DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: S. Gail Eckhardt, M.D. DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Maria C. Freire, Ph.D. DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Tomas J. Heyman DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: David E. Johnson DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Michael M. Morrissey, Ph.D. DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Robert L. Oliver, Jr. DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Stelios Papadopoulos, Ph.D. DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: George Poste, DVM, Ph.D., FRS DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Julie Anne Smith DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Jack L. Wyszomierski DIRECTOR ELECTIONS ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the focal year ending January 3, 2025. AUDIT-RELATED ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To amend and restate the Exelixis 2000 Employee Stock Purchase Plan to, among other things, increase the number of shares authorized for issuance by 6,000,000 shares. COMPENSATION ISSUER 599320.000000 0 FOR 599320.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement SECTION 14A SAY-ON-PAY VOTES ISSUER 599320.000000 0 FOR 599320.000000 FOR Glaukos Corporation 377322102 US3773221029 05/30/2024 Election of Directors: Thomas W. Burns DIRECTOR ELECTIONS ISSUER 41125.000000 0 FOR 41125.000000 FOR Glaukos Corporation 377322102 US3773221029 05/30/2024 Election of Directors: Leana S. Wen, M.D. DIRECTOR ELECTIONS ISSUER 41125.000000 0 FOR 41125.000000 FOR Glaukos Corporation 377322102 US3773221029 05/30/2024 Election of Directors: Marc A. Stapley DIRECTOR ELECTIONS ISSUER 41125.000000 0 FOR 41125.000000 FOR Glaukos Corporation 377322102 US3773221029 05/30/2024 Approval of the Glaukos Corporation Amended and Restated 2015 Omnibus Incentive Compensation Plan. COMPENSATION ISSUER 41125.000000 0 FOR 41125.000000 FOR Glaukos Corporation 377322102 US3773221029 05/30/2024 Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 41125.000000 0 ONE YEAR 41125.000000 FOR Glaukos Corporation 377322102 US3773221029 05/30/2024 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 41125.000000 0 FOR 41125.000000 FOR Glaukos Corporation 377322102 US3773221029 05/30/2024 Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 41125.000000 0 FOR 41125.000000 FOR Keros Therapeutics, Inc. 492327101 US4923271013 05/30/2024 To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Jasbir Seehra DIRECTOR ELECTIONS ISSUER 74602.000000 0 FOR 74602.000000 FOR Keros Therapeutics, Inc. 492327101 US4923271013 05/30/2024 To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Nima Farzan DIRECTOR ELECTIONS ISSUER 74602.000000 0 FOR 74602.000000 FOR Keros Therapeutics, Inc. 492327101 US4923271013 05/30/2024 To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Julius Knowles DIRECTOR ELECTIONS ISSUER 74602.000000 0 FOR 74602.000000 FOR Keros Therapeutics, Inc. 492327101 US4923271013 05/30/2024 To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. AUDIT-RELATED ISSUER 74602.000000 0 FOR 74602.000000 FOR Keros Therapeutics, Inc. 492327101 US4923271013 05/30/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 74602.000000 0 FOR 74602.000000 FOR Keros Therapeutics, Inc. 492327101 US4923271013 05/30/2024 To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 74602.000000 0 ONE YEAR 74602.000000 FOR Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/30/2024 To elect three Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Faraz Ali, M.B.A. DIRECTOR ELECTIONS ISSUER 580851.000000 0 FOR 580851.000000 FOR Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/30/2024 To elect three Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: June Lee, M.D. DIRECTOR ELECTIONS ISSUER 580851.000000 0 FOR 580851.000000 FOR Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/30/2024 To elect three Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Deepak Srivastava, M.D. DIRECTOR ELECTIONS ISSUER 580851.000000 0 FOR 580851.000000 FOR Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/30/2024 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 580851.000000 0 FOR 580851.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Emily Peterson Alva DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Shane M. Cooke DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: David A. Daglio, Jr. DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Richard B. Gaynor, M.D DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Cato T. Laurencin, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Nancy S. Lurker DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Brian P. McKeon DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Richard F. Pops DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Nancy L. Snyderman, M.D. DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Frank Anders Wilson DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Christopher I. Wright, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To approve, in a non-binding, advisory vote, the frequency of future advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 183485.000000 0 ONE YEAR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration. AUDIT-RELATED ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. COMPENSATION ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To renew Board authority to allot and issue shares under Irish law. CAPITAL STRUCTURE ISSUER 183485.000000 0 FOR 183485.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law. CAPITAL STRUCTURE ISSUER 183485.000000 0 FOR 183485.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. Austin DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Bradway DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. Drake DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. Druker DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Eckert DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. Garland DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr. DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar Ishrak DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler Jacks DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. Klotman DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. Kullman DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. Miles DIRECTOR ELECTIONS ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 Advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To approve our Amgen Inc. Second Amended and Restated 2009 Equity incentive Plan. COMPENSATION ISSUER 70253.000000 0 FOR 70253.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 70253.000000 0 FOR 70253.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 05/31/2024 ELECTION OF DIRECTORS: Jay Flatley DIRECTOR ELECTIONS ISSUER 289489.000000 0 FOR 289489.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 05/31/2024 ELECTION OF DIRECTORS: Marc Tessier-Lavigne, Ph.D. DIRECTOR ELECTIONS ISSUER 289489.000000 0 WITHHOLD 289489.000000 AGAINST Denali Therapeutics Inc. 24823R105 US24823R1059 05/31/2024 ELECTION OF DIRECTORS: Nancy Thornberry DIRECTOR ELECTIONS ISSUER 289489.000000 0 FOR 289489.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 05/31/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024 AUDIT-RELATED ISSUER 289489.000000 0 FOR 289489.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 05/31/2024 Advisory vote on executive compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 289489.000000 0 FOR 289489.000000 FOR Cabaletta Bio, Inc. 12674W109 US12674W1099 06/03/2024 To elect two class II directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Catherine Bollard, MBChB, M.D. DIRECTOR ELECTIONS ISSUER 506395.000000 0 WITHHOLD 506395.000000 AGAINST Cabaletta Bio, Inc. 12674W109 US12674W1099 06/03/2024 To elect two class II directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Richard Henriques, MBA DIRECTOR ELECTIONS ISSUER 506395.000000 0 FOR 506395.000000 FOR Cabaletta Bio, Inc. 12674W109 US12674W1099 06/03/2024 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 506395.000000 0 FOR 506395.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Charles Baker DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Timothy Flynn DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Paul Garcia DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Kristen Gil DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Stephen Hemsley DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Michele Hooper DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: F. William McNabb III DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Valerie Montgomery Rice, M.D. DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: John Noseworthy, M.D. DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Election of Directors: Andrew Witty DIRECTOR ELECTIONS ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2024. AUDIT-RELATED ISSUER 35155.000000 0 FOR 35155.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Report on Congruency of Political Spending with Company Values and Priorities OTHER SOCIAL ISSUES SECURITY HOLDER 35155.000000 0 AGAINST 35155.000000 FOR Morphic Holding, Inc. 61775R105 US61775R1059 06/04/2024 Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Gustav Christensen, MBA DIRECTOR ELECTIONS ISSUER 75190.000000 0 FOR 75190.000000 FOR Morphic Holding, Inc. 61775R105 US61775R1059 06/04/2024 Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Susannah Gray, MBA DIRECTOR ELECTIONS ISSUER 75190.000000 0 FOR 75190.000000 FOR Morphic Holding, Inc. 61775R105 US61775R1059 06/04/2024 Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Amir Nashat, Sc.D. DIRECTOR ELECTIONS ISSUER 75190.000000 0 WITHHOLD 75190.000000 AGAINST Morphic Holding, Inc. 61775R105 US61775R1059 06/04/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 75190.000000 0 FOR 75190.000000 FOR Morphic Holding, Inc. 61775R105 US61775R1059 06/04/2024 To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 75190.000000 0 FOR 75190.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Dawn Svoronos DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Gillian Cannon DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Steven Gannon DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Elizabeth Garofalo DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Justin Gover DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Pat Machado DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Ian Mortimer DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Election of Directors: Gary Patou DIRECTOR ELECTIONS ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Amendment to the Amended and Restated 2014 Plan Approve certain amendments to the Amended and Restated 2014 Equity Incentive Plan, including to increase the maximum number of Common Shares available for issuance thereunder by 5,200,000 COMPENSATION ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation or until their successors are duly elected AUDIT-RELATED ISSUER 420084.000000 0 FOR 420084.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2024 Remuneration of Auditor Authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditor of the Corporation AUDIT-RELATED ISSUER 420084.000000 0 FOR 420084.000000 FOR Annexon, Inc. 03589W102 US03589W1027 06/05/2024 To elect the two nominees for director to serve as Class I directors to hold office until the 2027 annual meeting of stockholders: William H. Carson, M.D. DIRECTOR ELECTIONS ISSUER 237835.000000 0 FOR 237835.000000 FOR Annexon, Inc. 03589W102 US03589W1027 06/05/2024 To elect the two nominees for director to serve as Class I directors to hold office until the 2027 annual meeting of stockholders: Muneer A. Satter DIRECTOR ELECTIONS ISSUER 237835.000000 0 FOR 237835.000000 FOR Annexon, Inc. 03589W102 US03589W1027 06/05/2024 To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 237835.000000 0 FOR 237835.000000 FOR Annexon, Inc. 03589W102 US03589W1027 06/05/2024 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 237835.000000 0 FOR 237835.000000 FOR Apellis Pharmaceuticals, Inc. 03753U106 US03753U1060 06/05/2024 Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Paul Fonteyne DIRECTOR ELECTIONS ISSUER 48790.000000 2600.000000 FOR 48790.000000 FOR Apellis Pharmaceuticals, Inc. 03753U106 US03753U1060 06/05/2024 Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Stephanie Monaghan O'Brien DIRECTOR ELECTIONS ISSUER 48790.000000 2600.000000 FOR 48790.000000 FOR Apellis Pharmaceuticals, Inc. 03753U106 US03753U1060 06/05/2024 Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; AUDIT-RELATED ISSUER 48790.000000 2600.000000 FOR 48790.000000 FOR Apellis Pharmaceuticals, Inc. 03753U106 US03753U1060 06/05/2024 Approval of an advisory vote on executive compensation; and SECTION 14A SAY-ON-PAY VOTES ISSUER 48790.000000 2600.000000 FOR 48790.000000 FOR Astria Therapeutics, Inc. 04635X102 US04635X1028 06/05/2024 The election of three Class III Directors to our Board of Directors, to serve for a three-year term until the 2027 annual meeting of stockholders: Sunil Agarwal DIRECTOR ELECTIONS ISSUER 129240.000000 0 FOR 129240.000000 FOR Astria Therapeutics, Inc. 04635X102 US04635X1028 06/05/2024 The election of three Class III Directors to our Board of Directors, to serve for a three-year term until the 2027 annual meeting of stockholders: Gregg Lapointe DIRECTOR ELECTIONS ISSUER 129240.000000 0 FOR 129240.000000 FOR Astria Therapeutics, Inc. 04635X102 US04635X1028 06/05/2024 The election of three Class III Directors to our Board of Directors, to serve for a three-year term until the 2027 annual meeting of stockholders: Jonathan Violin DIRECTOR ELECTIONS ISSUER 129240.000000 0 FOR 129240.000000 FOR Astria Therapeutics, Inc. 04635X102 US04635X1028 06/05/2024 The approval of the second amendment and restatement of our Amended and Restated 2015 Stock Incentive Plan, as amended, to, among other things, increase the number of shares of our common stock available for grant under the plan by 5,750,000 shares and extend the term of the plan to ten years from the date such second amendment and restatement is approved by our stockholders. COMPENSATION ISSUER 129240.000000 0 FOR 129240.000000 FOR Astria Therapeutics, Inc. 04635X102 US04635X1028 06/05/2024 The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 129240.000000 0 FOR 129240.000000 FOR Astria Therapeutics, Inc. 04635X102 US04635X1028 06/05/2024 The approval, by non-binding advisory vote, of our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 129240.000000 0 FOR 129240.000000 FOR Beam Therapeutics Inc. 07373V105 US07373V1052 06/05/2024 Election of the following nominee as a Class I Director for a three-year term ending at our Annual Meeting of Stockholders to be held in 2027: Graham Cooper DIRECTOR ELECTIONS ISSUER 237542.000000 0 FOR 237542.000000 FOR Beam Therapeutics Inc. 07373V105 US07373V1052 06/05/2024 Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 237542.000000 0 FOR 237542.000000 FOR Beam Therapeutics Inc. 07373V105 US07373V1052 06/05/2024 Approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 237542.000000 0 FOR 237542.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 1 - Ordinary Resolution THAT Dr. Olivier Brandicourt be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. DIRECTOR ELECTIONS ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 2 - Ordinary Resolution THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. DIRECTOR ELECTIONS ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 3 - Ordinary Resolution THAT Michael Goller be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. DIRECTOR ELECTIONS ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 4 - Ordinary Resolution THAT Dr. Corazon (Corsee) D. Sanders be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal. DIRECTOR ELECTIONS ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 5 - Ordinary Resolution THAT the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2024 be and is hereby approved, ratified and confirmed. AUDIT-RELATED ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 6 - Ordinary Resolution THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 7 - Ordinary Resolution THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares (which shall have the meaning ascribed to it under the HK Listing Rules coming into effect on June 11, 2024) out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved. CAPITAL STRUCTURE ISSUER 68555.000000 0 AGAINST 68555.000000 AGAINST BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 8 - Ordinary Resolution THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved. CAPITAL STRUCTURE ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 9 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the "Existing Shareholders"), up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year. CAPITAL STRUCTURE ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 10 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year. CAPITAL STRUCTURE ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 11 - Ordinary Resolution THAT the grant of restricted share units ("RSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the "2016 Plan"), according to the terms and conditions described in the Proxy Statement, be and is hereby approved. COMPENSATION ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 12 - Ordinary Resolution THAT the grant of performance share units ("PSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved. COMPENSATION ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 13 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$1,333,333 to Dr. Xiaodong Wang under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved. COMPENSATION ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 14 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$200,000 to each of the independent non-executive directors, Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, and Mr. Qingqing Yi, under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved. COMPENSATION ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 15 - Ordinary Resolution THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved. SECTION 14A SAY-ON-PAY VOTES ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 16 - Ordinary Resolution THAT, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved. SECTION 14A SAY-ON-PAY VOTES ISSUER 68555.000000 0 ONE YEAR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 17(a) - Ordinary Resolution THAT the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved. COMPENSATION ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 17(b) - Ordinary Resolution THAT the consultant sublimit set out in the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved. COMPENSATION ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 18 - Ordinary Resolution THAT the Fourth Amended and Restated 2018 Employee Share Purchase Plan of the Company, as described in the Proxy Statement, be and is hereby approved. COMPENSATION ISSUER 68555.000000 0 FOR 68555.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 19 - Ordinary Resolution THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved. CORPORATE GOVERNANCE ISSUER 68555.000000 0 FOR 68555.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Approve Allocation of Income and Dividends of EUR 1.25 per Share CAPITAL STRUCTURE ISSUER 263055.000000 0 FOR 263055.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Approve Discharge of Management Board for Fiscal Year 2023 CORPORATE GOVERNANCE ISSUER 263055.000000 0 FOR 263055.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Approve Discharge of Supervisory Board for Fiscal Year 2023 CORPORATE GOVERNANCE ISSUER 263055.000000 0 FOR 263055.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Ratify KPMG AG as Auditors for Fiscal Year 2024 AUDIT-RELATED ISSUER 263055.000000 0 FOR 263055.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Approve Remuneration Report COMPENSATION ISSUER 263055.000000 0 FOR 263055.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Elect Sidonie Golombowski-Daffner to the Supervisory Board DIRECTOR ELECTIONS ISSUER 263055.000000 0 FOR 263055.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Elect Dorothea Wenzel to the Supervisory Board DIRECTOR ELECTIONS ISSUER 263055.000000 0 FOR 263055.000000 FOR Gerresheimer AG D2852S109 DE000A0LD6E6 06/05/2024 Elect Christoph Zindel to the Supervisory Board DIRECTOR ELECTIONS ISSUER 263055.000000 0 FOR 263055.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Elect Yao Shanglong as Director DIRECTOR ELECTIONS ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Elect Xia Xinping as Director DIRECTOR ELECTIONS ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Elect Gu Huaming as Director DIRECTOR ELECTIONS ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Authorize Board to Fix Remuneration of Directors COMPENSATION ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Approve Ernst & Young as Auditors and Authorize Board to Fix Their Remuneration AUDIT-RELATED ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Authorize Repurchase of Issued Share Capital CAPITAL STRUCTURE ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights CAPITAL STRUCTURE ISSUER 4092500.000000 0 AGAINST 4092500.000000 AGAINST Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Authorize Reissuance of Repurchased Shares CAPITAL STRUCTURE ISSUER 4092500.000000 0 AGAINST 4092500.000000 AGAINST Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Amend Existing Tenth Amended and Restated Memorandum and Articles of Association and Adopt Eleventh Amended and Restated Memorandum and Articles of Association and Related Transactions CORPORATE GOVERNANCE ISSUER 4092500.000000 0 FOR 4092500.000000 FOR Kindstar Globalgene Technology, Inc. G5262E104 KYG5262E1044 06/05/2024 Approve Final Dividend CAPITAL STRUCTURE ISSUER 4092500.000000 0 FOR 4092500.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2024 Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Catherine Moukheibir DIRECTOR ELECTIONS ISSUER 107641.000000 6500.000000 FOR 107641.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2024 Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Ramnik Xavier DIRECTOR ELECTIONS ISSUER 107641.000000 6500.000000 FOR 107641.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2024 Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 107641.000000 6500.000000 FOR 107641.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2024 Approval of, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 107641.000000 6500.000000 FOR 107641.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2024 Non-binding advisory vote on the frequency of future advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 107641.000000 6500.000000 ONE YEAR 107641.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: Asaf Danziger DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: William Doyle DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: Jeryl Hilleman DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: David Hung DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: Kinyip Gabriel Leung DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: Martin Madden DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: Allyson Ocean DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: Timothy Scannell DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: Kristin Stafford DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 Election of Directors: William Vernon DIRECTOR ELECTIONS ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2024 AUDIT-RELATED ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 A non-binding advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 The approval of our 2024 Omnibus Incentive Plan COMPENSATION ISSUER 213335.000000 0 FOR 213335.000000 FOR NovoCure Limited G6674U108 JE00BYSS4X48 06/05/2024 A non-binding advisory vote to approve the frequency of the advisory vote on execute compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 213335.000000 0 ONE YEAR 213335.000000 FOR Penumbra, Inc. 70975L107 US70975L1070 06/05/2024 To elect the nominees for Class III director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Adam Elsesser DIRECTOR ELECTIONS ISSUER 59993.000000 0 FOR 59993.000000 FOR Penumbra, Inc. 70975L107 US70975L1070 06/05/2024 To elect the nominees for Class III director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Harpreet Grewal DIRECTOR ELECTIONS ISSUER 59993.000000 0 FOR 59993.000000 FOR Penumbra, Inc. 70975L107 US70975L1070 06/05/2024 To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra, Inc. for the fiscal year ending December 31, 2024; and AUDIT-RELATED ISSUER 59993.000000 0 FOR 59993.000000 FOR Penumbra, Inc. 70975L107 US70975L1070 06/05/2024 To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 59993.000000 0 FOR 59993.000000 FOR Sagimet Biosciences, Inc. 786700104 US7867001049 06/05/2024 The election of Class I directors for a three year term expiring in 2027: Paul Hoelscher DIRECTOR ELECTIONS ISSUER 358120.000000 50000.000000 FOR 358120.000000 FOR Sagimet Biosciences, Inc. 786700104 US7867001049 06/05/2024 The election of Class I directors for a three year term expiring in 2027: Timothy P. Walbert DIRECTOR ELECTIONS ISSUER 358120.000000 50000.000000 FOR 358120.000000 FOR Sagimet Biosciences, Inc. 786700104 US7867001049 06/05/2024 The ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 358120.000000 50000.000000 FOR 358120.000000 FOR Stoke Therapeutics, Inc. 86150R107 US86150R1077 06/05/2024 Election of Class II Directors to serve until the 2027 annual meeting of shareholders or until their successor has been duly elected and qualified: Jennifer C. Burstein DIRECTOR ELECTIONS ISSUER 487988.000000 0 FOR 487988.000000 FOR Stoke Therapeutics, Inc. 86150R107 US86150R1077 06/05/2024 Election of Class II Directors to serve until the 2027 annual meeting of shareholders or until their successor has been duly elected and qualified: Arthur A. Levin DIRECTOR ELECTIONS ISSUER 487988.000000 0 FOR 487988.000000 FOR Stoke Therapeutics, Inc. 86150R107 US86150R1077 06/05/2024 Election of Class II Directors to serve until the 2027 annual meeting of shareholders or until their successor has been duly elected and qualified: Ian F. Smith DIRECTOR ELECTIONS ISSUER 487988.000000 0 FOR 487988.000000 FOR Stoke Therapeutics, Inc. 86150R107 US86150R1077 06/05/2024 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 487988.000000 0 FOR 487988.000000 FOR Voyager Therapeutics, Inc. 92915B106 US92915B1061 06/05/2024 To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Michael Higgins DIRECTOR ELECTIONS ISSUER 310205.000000 39500.000000 FOR 310205.000000 FOR Voyager Therapeutics, Inc. 92915B106 US92915B1061 06/05/2024 To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Jude Onyia DIRECTOR ELECTIONS ISSUER 310205.000000 39500.000000 FOR 310205.000000 FOR Voyager Therapeutics, Inc. 92915B106 US92915B1061 06/05/2024 To elect each of the following directors to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nancy Vitale DIRECTOR ELECTIONS ISSUER 310205.000000 39500.000000 FOR 310205.000000 FOR Voyager Therapeutics, Inc. 92915B106 US92915B1061 06/05/2024 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 310205.000000 39500.000000 FOR 310205.000000 FOR Voyager Therapeutics, Inc. 92915B106 US92915B1061 06/05/2024 To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 310205.000000 39500.000000 FOR 310205.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/06/2024 Election of Directors: Kathryn Falberg DIRECTOR ELECTIONS ISSUER 136690.000000 33100.000000 FOR 136690.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/06/2024 Election of Directors: Linda Higgins, Ph.D. DIRECTOR ELECTIONS ISSUER 136690.000000 33100.000000 FOR 136690.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/06/2024 Election of Directors: Terry Rosen, Ph.D. DIRECTOR ELECTIONS ISSUER 136690.000000 33100.000000 FOR 136690.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/06/2024 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of Arcus Biosciences for its fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 136690.000000 33100.000000 FOR 136690.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/06/2024 To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 136690.000000 33100.000000 FOR 136690.000000 FOR Black Diamond Therapeutics, Inc. 09203E105 US09203E1055 06/06/2024 Election of Class I Directors: Prakash Raman DIRECTOR ELECTIONS ISSUER 817550.000000 16000.000000 FOR 817550.000000 FOR Black Diamond Therapeutics, Inc. 09203E105 US09203E1055 06/06/2024 Election of Class I Directors: Mark A. Velleca DIRECTOR ELECTIONS ISSUER 817550.000000 16000.000000 FOR 817550.000000 FOR Black Diamond Therapeutics, Inc. 09203E105 US09203E1055 06/06/2024 To ratify the appointment of PricewaterhouseCoopers LLP as Black Diamond Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 817550.000000 16000.000000 FOR 817550.000000 FOR Black Diamond Therapeutics, Inc. 09203E105 US09203E1055 06/06/2024 To approve an amendment to Black Diamond Therapeutics, Inc.'s Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain of its officers as permitted by Delaware law. CORPORATE GOVERNANCE ISSUER 817550.000000 16000.000000 FOR 817550.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/06/2024 Election of Directors: Brett P. Monia DIRECTOR ELECTIONS ISSUER 159555.000000 0 FOR 159555.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/06/2024 Election of Directors: Michael Yang DIRECTOR ELECTIONS ISSUER 159555.000000 0 FOR 159555.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/06/2024 To make an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 159555.000000 0 FOR 159555.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/06/2024 To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 3,300,000 shares to an aggregate of 38,500,000 shares and to prohibit certain share recycling on full value awards. COMPENSATION ISSUER 159555.000000 0 FOR 159555.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/06/2024 To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year. AUDIT-RELATED ISSUER 159555.000000 0 FOR 159555.000000 FOR Sana Biotechnology, Inc. 799566104 US7995661045 06/06/2024 To elect three Class III directors to our Board of Directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election are: Joshua H. Bilenker, M.D. DIRECTOR ELECTIONS ISSUER 330182.000000 0 FOR 330182.000000 FOR Sana Biotechnology, Inc. 799566104 US7995661045 06/06/2024 To elect three Class III directors to our Board of Directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election are: Richard Mulligan, Ph.D. DIRECTOR ELECTIONS ISSUER 330182.000000 0 FOR 330182.000000 FOR Sana Biotechnology, Inc. 799566104 US7995661045 06/06/2024 To elect three Class III directors to our Board of Directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election are: Mary Agnes (Maggie) Wilderotter DIRECTOR ELECTIONS ISSUER 330182.000000 0 FOR 330182.000000 FOR Sana Biotechnology, Inc. 799566104 US7995661045 06/06/2024 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 330182.000000 0 FOR 330182.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/06/2024 to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. Ingram DIRECTOR ELECTIONS ISSUER 52629.000000 0 FOR 52629.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/06/2024 to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Hans Wigzell, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 52629.000000 0 FOR 52629.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/06/2024 to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn J. Boor, Ph.D. DIRECTOR ELECTIONS ISSUER 52629.000000 0 FOR 52629.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/06/2024 to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Michael Chambers DIRECTOR ELECTIONS ISSUER 52629.000000 0 FOR 52629.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/06/2024 advisory vote to approve, on a non-binding basis, name executive officer compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 52629.000000 0 FOR 52629.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/06/2024 ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2024 AUDIT-RELATED ISSUER 52629.000000 0 FOR 52629.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/06/2024 Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Annie Drapeau DIRECTOR ELECTIONS ISSUER 274070.000000 0 FOR 274070.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/06/2024 Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Teri Loxam DIRECTOR ELECTIONS ISSUER 274070.000000 0 FOR 274070.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/06/2024 Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Carlos Paya, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 274070.000000 0 FOR 274070.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/06/2024 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 274070.000000 0 FOR 274070.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/06/2024 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 274070.000000 0 FOR 274070.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/07/2024 Election of Directors: Herriot Tabuteau, M.D. DIRECTOR ELECTIONS ISSUER 38160.000000 0 FOR 38160.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/07/2024 Election of Directors: Mark Coleman, M.D. DIRECTOR ELECTIONS ISSUER 38160.000000 0 FOR 38160.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/07/2024 To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 38160.000000 0 FOR 38160.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/07/2024 To approve, by non-binding advisory vote, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 38160.000000 0 FOR 38160.000000 FOR SAGE Therapeutics, Inc. 78667J108 US78667J1088 06/10/2024 To elect two directors, Elizabeth Barrett and Geno Germano, each to serve as a Class I director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal: Elizabeth Barrett DIRECTOR ELECTIONS ISSUER 253320.000000 0 WITHHOLD 253320.000000 AGAINST SAGE Therapeutics, Inc. 78667J108 US78667J1088 06/10/2024 To elect two directors, Elizabeth Barrett and Geno Germano, each to serve as a Class I director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal: Geno Germano DIRECTOR ELECTIONS ISSUER 253320.000000 0 FOR 253320.000000 FOR SAGE Therapeutics, Inc. 78667J108 US78667J1088 06/10/2024 To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 AUDIT-RELATED ISSUER 253320.000000 0 FOR 253320.000000 FOR SAGE Therapeutics, Inc. 78667J108 US78667J1088 06/10/2024 To hold a non-binding advisory vote to approve the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 253320.000000 0 FOR 253320.000000 FOR SAGE Therapeutics, Inc. 78667J108 US78667J1088 06/10/2024 To approve the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. COMPENSATION ISSUER 253320.000000 0 FOR 253320.000000 FOR 10X Genomics, Inc. 88025U109 US88025U1097 06/11/2024 Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to serve a three-year term expiring at the 2027 annual meeting of stockholders or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal; Kimberly J. Popovits DIRECTOR ELECTIONS ISSUER 228435.000000 3500.000000 FOR 228435.000000 FOR 10X Genomics, Inc. 88025U109 US88025U1097 06/11/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; AUDIT-RELATED ISSUER 228435.000000 3500.000000 FOR 228435.000000 FOR 10X Genomics, Inc. 88025U109 US88025U1097 06/11/2024 A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our board of directors without requiring stockholder approval; CORPORATE GOVERNANCE ISSUER 228435.000000 3500.000000 AGAINST 228435.000000 AGAINST 10X Genomics, Inc. 88025U109 US88025U1097 06/11/2024 A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and SECTION 14A SAY-ON-PAY VOTES ISSUER 228435.000000 3500.000000 AGAINST 228435.000000 AGAINST Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Iain Dukes, D. Phil. DIRECTOR ELECTIONS ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Athena Countouriotis, M.D. DIRECTOR ELECTIONS ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Ryan Maynard DIRECTOR ELECTIONS ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wayne P. Rothbaum DIRECTOR ELECTIONS ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D. DIRECTOR ELECTIONS ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Michael Weiser M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wendy Yarno DIRECTOR ELECTIONS ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To approve, by non-binding advisory vote, the compensation of our named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024; AUDIT-RELATED ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from our 2014 Equity Incentive Plan; and COMPENSATION ISSUER 168215.000000 0 FOR 168215.000000 FOR Iovance Biotherapeutics, Inc. 462260100 US4622601007 06/11/2024 To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares. COMPENSATION ISSUER 168215.000000 0 FOR 168215.000000 FOR Biomea Fusion, Inc. 09077A106 US09077A1060 06/12/2024 The election of Thomas Butler and Michael J. M. Hitchcock, Ph.D., as Class III Directors, to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027: Thomas Butler DIRECTOR ELECTIONS ISSUER 106315.000000 39900.000000 FOR 106315.000000 FOR Biomea Fusion, Inc. 09077A106 US09077A1060 06/12/2024 The election of Thomas Butler and Michael J. M. Hitchcock, Ph.D., as Class III Directors, to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027: J.M. Hitchcock, Ph.D. DIRECTOR ELECTIONS ISSUER 106315.000000 39900.000000 WITHHOLD 106315.000000 AGAINST Biomea Fusion, Inc. 09077A106 US09077A1060 06/12/2024 To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 106315.000000 39900.000000 FOR 106315.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Election of Directors: Daniella Beckman DIRECTOR ELECTIONS ISSUER 321440.000000 0 FOR 321440.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Election of Directors: Habib Dable DIRECTOR ELECTIONS ISSUER 321440.000000 0 FOR 321440.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Election of Directors: Lynn Seely DIRECTOR ELECTIONS ISSUER 321440.000000 0 FOR 321440.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Approval of a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 321440.000000 0 ONE YEAR 321440.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Approval of a non-binding advisory vote on the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 321440.000000 0 FOR 321440.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Approval of the Blueprint Medicines Corporation 2024 Stock Incentive Plan. COMPENSATION ISSUER 321440.000000 0 FOR 321440.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 321440.000000 0 FOR 321440.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/12/2024 Election of Class III Directors: Helmy Eltoukhy DIRECTOR ELECTIONS ISSUER 338605.000000 4300.000000 FOR 338605.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/12/2024 Election of Class III Directors: Steve Krognes DIRECTOR ELECTIONS ISSUER 338605.000000 4300.000000 WITHHOLD 338605.000000 AGAINST Guardant Health, Inc. 40131M109 US40131M1099 06/12/2024 Election of Class III Directors: AmirAli Talasaz DIRECTOR ELECTIONS ISSUER 338605.000000 4300.000000 FOR 338605.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/12/2024 Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 338605.000000 4300.000000 FOR 338605.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/12/2024 Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 338605.000000 4300.000000 FOR 338605.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Julian C. Baker DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Jean-Jacques Bienaime DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Otis W. Brawley DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Paul J. Clancy DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Jacqualyn A. Fouse DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Edmund P. Harrigan DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Katherine A. High DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Herve Hoppenot DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Election of Directors: Susanne Schaffert DIRECTOR ELECTIONS ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 114060.000000 0 FOR 114060.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 114060.000000 0 FOR 114060.000000 FOR Monte Rosa Therapeutics, Inc. 61225M102 US61225M1027 06/12/2024 To elect two Class III director nominees to our board of directors, to serve until the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Markus Warmuth DIRECTOR ELECTIONS ISSUER 266168.000000 0 FOR 266168.000000 FOR Monte Rosa Therapeutics, Inc. 61225M102 US61225M1027 06/12/2024 To elect two Class III director nominees to our board of directors, to serve until the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Ali Behbahani DIRECTOR ELECTIONS ISSUER 266168.000000 0 WITHHOLD 266168.000000 AGAINST Monte Rosa Therapeutics, Inc. 61225M102 US61225M1027 06/12/2024 To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 and AUDIT-RELATED ISSUER 266168.000000 0 FOR 266168.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/12/2024 Election of the following nominees as Class III directors: Emily Drabant Conley, Ph.D. DIRECTOR ELECTIONS ISSUER 202615.000000 9700.000000 FOR 202615.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/12/2024 Election of the following nominees as Class III directors: Sapna Srivastava, Ph.D. DIRECTOR ELECTIONS ISSUER 202615.000000 9700.000000 FOR 202615.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/12/2024 Election of the following nominees as Class III directors: Cameron Wheeler, Ph.D. DIRECTOR ELECTIONS ISSUER 202615.000000 9700.000000 FOR 202615.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/12/2024 To approve, on an advisory basis, the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 202615.000000 9700.000000 FOR 202615.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/12/2024 To approve, on an advisory basis, the frequency of future advisory votes to approve the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 202615.000000 9700.000000 ONE YEAR 202615.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/12/2024 To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 202615.000000 9700.000000 FOR 202615.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Approve Financial Statements and Allocation of Income CAPITAL STRUCTURE CORPORATE GOVERNANCE ISSUER 630441.000000 0 FOR 630441.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Approve Discharge of Directors CORPORATE GOVERNANCE ISSUER 630441.000000 0 FOR 630441.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Approve Discharge of Auditors AUDIT-RELATED CORPORATE GOVERNANCE ISSUER 630441.000000 0 FOR 630441.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Approve Remuneration Report COMPENSATION ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Approve Amended Remuneration Policy COMPENSATION ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Elect Robelga SRL, Permanently Represented by Robert Taub, as Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Reelect Jurgen Hambrecht as Independent Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Reelect Kevin Rakin as Independent Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 FOR 630441.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Reelect Rita Johnson-Mills as Independent Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Reelect Virginia Kirby as Independent Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 FOR 630441.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Reelect Wildman Ventures LLC Permanently Represented by Daniel Wildman, as Independent Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Reelect Pierre Gianello as Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 FOR 630441.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Reelect Olivier Taelman as Director DIRECTOR ELECTIONS ISSUER 630441.000000 0 FOR 630441.000000 FOR Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Renew Authorization to Increase Share Capital within the Framework of Authorized Capital and Amend Article 7 Accordingly CAPITAL STRUCTURE ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Nyxoah SA B6S7WD106 BE0974358906 06/12/2024 Authorize Filing of Required Documents/Formalities at Trade Registry CORPORATE GOVERNANCE ISSUER 630441.000000 0 AGAINST 630441.000000 AGAINST Prime Medicine, Inc. 74168J101 US74168J1016 06/12/2024 To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Wendy Chung, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 412139.000000 0 WITHHOLD 412139.000000 AGAINST Prime Medicine, Inc. 74168J101 US74168J1016 06/12/2024 To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Kaye Foster DIRECTOR ELECTIONS ISSUER 412139.000000 0 FOR 412139.000000 FOR Prime Medicine, Inc. 74168J101 US74168J1016 06/12/2024 To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Keith Gottesdiener, M.D. DIRECTOR ELECTIONS ISSUER 412139.000000 0 FOR 412139.000000 FOR Prime Medicine, Inc. 74168J101 US74168J1016 06/12/2024 To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Jeffrey Marrazzo DIRECTOR ELECTIONS ISSUER 412139.000000 0 FOR 412139.000000 FOR Prime Medicine, Inc. 74168J101 US74168J1016 06/12/2024 To approve an amendment to our Third Amended and Restated Certificate of Incorporation to limit the liability of certain of our officers as permitted by Delaware law. CORPORATE GOVERNANCE ISSUER 412139.000000 0 FOR 412139.000000 FOR Prime Medicine, Inc. 74168J101 US74168J1016 06/12/2024 To ratify the appointment of PricewaterhouseCoopers LLP as our Independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 412139.000000 0 FOR 412139.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The election of seven nominees as directors to hold office until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified: Howard G. Berger, M.D. DIRECTOR ELECTIONS ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The election of seven nominees as directors to hold office until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified: Christine N. Gordon DIRECTOR ELECTIONS ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The election of seven nominees as directors to hold office until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified: A. Gregory Sorensen, M.D. DIRECTOR ELECTIONS ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The election of seven nominees as directors to hold office until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified: Laura P. Jacobs DIRECTOR ELECTIONS ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The election of seven nominees as directors to hold office until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified: Lawrence L. Levitt DIRECTOR ELECTIONS ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The election of seven nominees as directors to hold office until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified: Gregory E. Spurlock DIRECTOR ELECTIONS ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The election of seven nominees as directors to hold office until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified: David L. Swartz DIRECTOR ELECTIONS ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; AUDIT-RELATED ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR RadNet, Inc. 750491102 US7504911022 06/12/2024 A non-binding advisory vote to approve the compensation of our Named Executive Officers; and SECTION 14A SAY-ON-PAY VOTES ISSUER 52275.000000 8600.000000 FOR 52275.000000 FOR TScan Therapeutics, Inc. 89854M101 US89854M1018 06/12/2024 To elect two Class III directors to the Company's Board of Directors: Gabriela Gruia, M.D. DIRECTOR ELECTIONS ISSUER 1045767.000000 0 FOR 1045767.000000 FOR TScan Therapeutics, Inc. 89854M101 US89854M1018 06/12/2024 To elect two Class III directors to the Company's Board of Directors: Barbara Klencke, M.D. DIRECTOR ELECTIONS ISSUER 1045767.000000 0 FOR 1045767.000000 FOR TScan Therapeutics, Inc. 89854M101 US89854M1018 06/12/2024 To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 AUDIT-RELATED ISSUER 1045767.000000 0 FOR 1045767.000000 FOR TScan Therapeutics, Inc. 89854M101 US89854M1018 06/12/2024 To approve the Company's Amended and Restated 2021 Equity Incentive Plan COMPENSATION ISSUER 1045767.000000 0 AGAINST 1045767.000000 AGAINST 908 Devices Inc. 65443P102 US65443P1021 06/13/2024 To elect two Class I directors to hold office until the 2027 annual meeting of stockholders: Fenel M. Eloi DIRECTOR ELECTIONS ISSUER 265584.000000 8500.000000 WITHHOLD 265584.000000 AGAINST 908 Devices Inc. 65443P102 US65443P1021 06/13/2024 To elect two Class I directors to hold office until the 2027 annual meeting of stockholders: Jeffrey P. George DIRECTOR ELECTIONS ISSUER 265584.000000 8500.000000 WITHHOLD 265584.000000 AGAINST 908 Devices Inc. 65443P102 US65443P1021 06/13/2024 To ratify, on an advisory basis, the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 265584.000000 8500.000000 FOR 265584.000000 FOR Exact Sciences Corporation 30063P105 US30063P1057 06/13/2024 To elect three members of the Board of Directors to serve for one-year terms as Class III Directors: Michael Barber DIRECTOR ELECTIONS ISSUER 96280.000000 11600.000000 FOR 96280.000000 FOR Exact Sciences Corporation 30063P105 US30063P1057 06/13/2024 To elect three members of the Board of Directors to serve for one-year terms as Class III Directors: Paul Clancy DIRECTOR ELECTIONS ISSUER 96280.000000 11600.000000 FOR 96280.000000 FOR Exact Sciences Corporation 30063P105 US30063P1057 06/13/2024 To elect three members of the Board of Directors to serve for one-year terms as Class III Directors: Daniel Levangie DIRECTOR ELECTIONS ISSUER 96280.000000 11600.000000 FOR 96280.000000 FOR Exact Sciences Corporation 30063P105 US30063P1057 06/13/2024 To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 96280.000000 11600.000000 FOR 96280.000000 FOR Exact Sciences Corporation 30063P105 US30063P1057 06/13/2024 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 96280.000000 11600.000000 FOR 96280.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Elisabeth Bjork, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Carsten Boess DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Pedro Granadillo DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Gotham Makker, M.D. DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Fady Malik, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Gaurav Shah, M.D. DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: David P. Southwell DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Roderick Wong, M.D. DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: R. Keith Woods DIRECTOR ELECTIONS ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Election of Directors: Naveen Yalamanchi, M.D. DIRECTOR ELECTIONS ISSUER 252097.000000 0 WITHHOLD 252097.000000 AGAINST Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis. SECTION 14A SAY-ON-PAY VOTES ISSUER 252097.000000 0 FOR 252097.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Approval of an amendment to the Company's Seventh Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock. CAPITAL STRUCTURE ISSUER 252097.000000 0 FOR 252097.000000 FOR Tarsus Pharmaceuticals, Inc. 87650L103 US87650L1035 06/13/2024 To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: Bhaskar Chaudhuri DIRECTOR ELECTIONS ISSUER 130465.000000 13700.000000 FOR 130465.000000 FOR Tarsus Pharmaceuticals, Inc. 87650L103 US87650L1035 06/13/2024 To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: William J. Link DIRECTOR ELECTIONS ISSUER 130465.000000 13700.000000 FOR 130465.000000 FOR Tarsus Pharmaceuticals, Inc. 87650L103 US87650L1035 06/13/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 130465.000000 13700.000000 FOR 130465.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: Dr. Peter Farrell DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: Joseph E. Payne DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: Andy Sassine DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: James Barlow DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: Dr. Edward W. Holmes DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: Dr. Magda Marquet DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: Dr. Jing L. Marantz DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval of the election of the following individuals as directors of the Company, to serve until the next annual meeting of stockholders: Dr. John Markels DIRECTOR ELECTIONS ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 To approve an amendment to the Amended and Restated 2019 Omnibus Equity Incentive Plan (as amended, the "Plan") to, among other things, increase the maximum number of shares of common stock available to Plan participants thereunder by 2,000,000 shares to an aggregate of 10,750,000 shares, as provided in Proposal Number 2 of the Proxy Statement. COMPENSATION ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Approval, by non-binding advisory vote, of the resolution approving the Company's Named Executive Officer compensation, as provided in Proposal Number 3 of the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 103675.000000 0 FOR 103675.000000 FOR Arcturus Therapeutics Holdings Inc. 03969T109 US03969T1097 06/14/2024 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 103675.000000 0 FOR 103675.000000 FOR Neurogene, Inc. 64135M105 US64135M1053 06/14/2024 Election of Class I Directors for terms expiring in 2027: Cory Freedland DIRECTOR ELECTIONS ISSUER 339050.000000 33000.000000 FOR 339050.000000 FOR Neurogene, Inc. 64135M105 US64135M1053 06/14/2024 Election of Class I Directors for terms expiring in 2027: Rachel McMinn DIRECTOR ELECTIONS ISSUER 339050.000000 33000.000000 FOR 339050.000000 FOR Neurogene, Inc. 64135M105 US64135M1053 06/14/2024 To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 339050.000000 33000.000000 FOR 339050.000000 FOR Neurogene, Inc. 64135M105 US64135M1053 06/14/2024 To ratify on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting rm for the year ending December 31, 2024. AUDIT-RELATED ISSUER 339050.000000 33000.000000 FOR 339050.000000 FOR PTC Therapeutics, Inc. 69366J200 US69366J2006 06/18/2024 Election of Four Class II Directors: Emma Reeve DIRECTOR ELECTIONS ISSUER 225815.000000 0 FOR 225815.000000 FOR PTC Therapeutics, Inc. 69366J200 US69366J2006 06/18/2024 Election of Four Class II Directors: Michael Schmertzler DIRECTOR ELECTIONS ISSUER 225815.000000 0 FOR 225815.000000 FOR PTC Therapeutics, Inc. 69366J200 US69366J2006 06/18/2024 Election of Four Class II Directors: Mary Smith DIRECTOR ELECTIONS ISSUER 225815.000000 0 FOR 225815.000000 FOR PTC Therapeutics, Inc. 69366J200 US69366J2006 06/18/2024 Election of Four Class II Directors: Glenn D. Steele, Jr., M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 225815.000000 0 FOR 225815.000000 FOR PTC Therapeutics, Inc. 69366J200 US69366J2006 06/18/2024 Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 225815.000000 0 FOR 225815.000000 FOR PTC Therapeutics, Inc. 69366J200 US69366J2006 06/18/2024 Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 225815.000000 0 FOR 225815.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 06/18/2024 Nominees: Deborah Dunsire, M.D. DIRECTOR ELECTIONS ISSUER 118142.000000 0 FOR 118142.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 06/18/2024 Nominees: Michael Narachi DIRECTOR ELECTIONS ISSUER 118142.000000 0 FOR 118142.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 06/18/2024 Nominees: Corsee D. Sanders, Ph.D. DIRECTOR ELECTIONS ISSUER 118142.000000 0 FOR 118142.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 06/18/2024 Approval of the Amended and Restated 2023 Incentive Plan. COMPENSATION ISSUER 118142.000000 0 FOR 118142.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 06/18/2024 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 118142.000000 0 FOR 118142.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 06/18/2024 Advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 118142.000000 0 FOR 118142.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Approve Remuneration Report (Non-Binding) COMPENSATION ISSUER 752390.000000 0 AGAINST 752390.000000 AGAINST AC Immune SA H00263105 CH0329023102 06/20/2024 Approve Treatment of Net Loss CAPITAL STRUCTURE ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Approve Discharge of Board and Senior Management CORPORATE GOVERNANCE ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Approve Remuneration of Directors in the Amount of CHF 883,000 COMPENSATION ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Approve Remuneration of Executive Committee in the Amount of CHF 7.6 Million COMPENSATION ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reelect Douglas Williams as Director and Board Chair DIRECTOR ELECTIONS ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reelect Monika Buetler as Director DIRECTOR ELECTIONS ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reelect Carl June as Director DIRECTOR ELECTIONS ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reelect Werner Lanthaler as Director DIRECTOR ELECTIONS ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reelect Andrea Pfeifer as Director DIRECTOR ELECTIONS ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reelect Monica Shaw as Director DIRECTOR ELECTIONS ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reelect Roy Twyman as Director DIRECTOR ELECTIONS ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Reappoint Monika Buetler as Member of the Compensation, Nomination and Corporate Governance Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 752390.000000 0 AGAINST 752390.000000 AGAINST AC Immune SA H00263105 CH0329023102 06/20/2024 Reappoint Roy Twyman as Member of the Compensation, Nomination and Corporate Governance Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 752390.000000 0 AGAINST 752390.000000 AGAINST AC Immune SA H00263105 CH0329023102 06/20/2024 Reappoint Douglas Williams as Member of the Compensation, Nomination and Corporate Governance Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 752390.000000 0 AGAINST 752390.000000 AGAINST AC Immune SA H00263105 CH0329023102 06/20/2024 Ratify PricewaterhouseCoopers SA as Auditors AUDIT-RELATED ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Designate Reymond & Associes as Independent Proxy CORPORATE GOVERNANCE ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Approve Creation of Capital Band within the Upper Limit of CHF 2.9 Million and the Lower Limit of CHF 2.1 Million with or without Exclusion of Preemptive Rights CAPITAL STRUCTURE ISSUER 752390.000000 0 AGAINST 752390.000000 AGAINST AC Immune SA H00263105 CH0329023102 06/20/2024 Approve Creation of CHF 129,844 Pool of Conditional Capital for Employee Equity Plans COMPENSATION ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Amend Articles Re: Shares and Share Register CORPORATE GOVERNANCE ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Amend Articles of Association (Incl. Approval of Virtual-Only or Hybrid Shareholder Meetings) CORPORATE GOVERNANCE ISSUER 752390.000000 0 FOR 752390.000000 FOR AC Immune SA H00263105 CH0329023102 06/20/2024 Transact Other Business (Voting) CORPORATE GOVERNANCE ISSUER 752390.000000 0 ABSTAIN 752390.000000 AGAINST Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Caroline D. Dorsa DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Maria C. Freire DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: William A. Hawkins DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Susan K. Langer DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Jesus B. Mantas DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Monish Patolawala DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Eric K. Rowinsky DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Stephen A. Sherwin DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Christopher A. Viehbacher DIRECTOR ELECTIONS ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Say on Pay - To hold an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 To approve an amendment to Biogen's Amended and Restated Certificate of Incorporation, as amended, to add an officer exculpation provision. CORPORATE GOVERNANCE ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 To approve the Biogen Inc. 2024 Omnibus Plan. COMPENSATION ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 To approve the Biogen Inc. 2024 Employee Stock Purchase Plan. COMPENSATION ISSUER 94215.000000 5000.000000 FOR 94215.000000 FOR Immatics N.V. N44445109 NL0015285941 06/20/2024 Adopt Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 256778.000000 0 FOR 256778.000000 FOR Immatics N.V. N44445109 NL0015285941 06/20/2024 Approve Discharge of Directors CORPORATE GOVERNANCE ISSUER 256778.000000 0 FOR 256778.000000 FOR Immatics N.V. N44445109 NL0015285941 06/20/2024 Reelect M.G. Atieh as Non-Executive Director Class I DIRECTOR ELECTIONS ISSUER 256778.000000 0 FOR 256778.000000 FOR Immatics N.V. N44445109 NL0015285941 06/20/2024 Reelect P.R. Carter as Non-Executive Director Class I DIRECTOR ELECTIONS ISSUER 256778.000000 0 AGAINST 256778.000000 AGAINST Immatics N.V. N44445109 NL0015285941 06/20/2024 Elect E.R. Forster as Non-Executive Director Class I DIRECTOR ELECTIONS ISSUER 256778.000000 0 AGAINST 256778.000000 AGAINST Immatics N.V. N44445109 NL0015285941 06/20/2024 Grant Board Authority to Issue Shares or to Grant Rights to Subscribe for Ordinary Shares CAPITAL STRUCTURE ISSUER 256778.000000 0 AGAINST 256778.000000 AGAINST Immatics N.V. N44445109 NL0015285941 06/20/2024 Authorize Board to Exclude Preemptive Rights from Share Issuances CAPITAL STRUCTURE ISSUER 256778.000000 0 AGAINST 256778.000000 AGAINST Immatics N.V. N44445109 NL0015285941 06/20/2024 Authorize Repurchase of Ordinary Shares or Depositary Receipts CAPITAL STRUCTURE ISSUER 256778.000000 0 AGAINST 256778.000000 AGAINST Immatics N.V. N44445109 NL0015285941 06/20/2024 Approve 2024 Stock Option and Incentive Plan COMPENSATION ISSUER 256778.000000 0 AGAINST 256778.000000 AGAINST Immatics N.V. N44445109 NL0015285941 06/20/2024 Ratify PricewaterhouseCoopers Accountants N.V. as Auditors AUDIT-RELATED ISSUER 256778.000000 0 FOR 256778.000000 FOR Orchestra Biomed Holdings, Inc. 68572M106 US68572M1062 06/20/2024 Election of Class I Directors: Eric A. Rose, M.D. DIRECTOR ELECTIONS ISSUER 233344.000000 0 WITHHOLD 233344.000000 AGAINST Orchestra Biomed Holdings, Inc. 68572M106 US68572M1062 06/20/2024 Election of Class I Directors: Jason Aryeh DIRECTOR ELECTIONS ISSUER 233344.000000 0 FOR 233344.000000 FOR Orchestra Biomed Holdings, Inc. 68572M106 US68572M1062 06/20/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 233344.000000 0 FOR 233344.000000 FOR Protagonist Therapeutics, Inc. 74366E102 US74366E1029 06/20/2024 To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Sarah A. O'Dowd DIRECTOR ELECTIONS ISSUER 421725.000000 0 FOR 421725.000000 FOR Protagonist Therapeutics, Inc. 74366E102 US74366E1029 06/20/2024 To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: William D. Waddill DIRECTOR ELECTIONS ISSUER 421725.000000 0 FOR 421725.000000 FOR Protagonist Therapeutics, Inc. 74366E102 US74366E1029 06/20/2024 To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Lewis T. "Rusty" Williams, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 421725.000000 0 FOR 421725.000000 FOR Protagonist Therapeutics, Inc. 74366E102 US74366E1029 06/20/2024 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 421725.000000 0 FOR 421725.000000 FOR Protagonist Therapeutics, Inc. 74366E102 US74366E1029 06/20/2024 To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 421725.000000 0 FOR 421725.000000 FOR Protagonist Therapeutics, Inc. 74366E102 US74366E1029 06/20/2024 To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 90,000,000 to 180,000,000. CAPITAL STRUCTURE ISSUER 421725.000000 0 FOR 421725.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/20/2024 To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Elizabeth McKee Anderson DIRECTOR ELECTIONS ISSUER 181447.000000 0 FOR 181447.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/20/2024 To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Flavia Borellini, Ph.D. DIRECTOR ELECTIONS ISSUER 181447.000000 0 FOR 181447.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/20/2024 To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Lorence Kim, M.D. DIRECTOR ELECTIONS ISSUER 181447.000000 0 FOR 181447.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/20/2024 To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and AUDIT-RELATED ISSUER 181447.000000 0 FOR 181447.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/20/2024 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 181447.000000 0 FOR 181447.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Eric Aguiar, M.D. DIRECTOR ELECTIONS ISSUER 169445.000000 0 FOR 169445.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Jennifer E. Cook DIRECTOR ELECTIONS ISSUER 169445.000000 0 FOR 169445.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Andrea J. Ellis DIRECTOR ELECTIONS ISSUER 169445.000000 0 FOR 169445.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Fred Hassan DIRECTOR ELECTIONS ISSUER 169445.000000 0 FOR 169445.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Ali J. Satvat DIRECTOR ELECTIONS ISSUER 169445.000000 0 WITHHOLD 169445.000000 AGAINST BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 169445.000000 0 FOR 169445.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 169445.000000 0 FOR 169445.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares. COMPENSATION ISSUER 169445.000000 0 FOR 169445.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Adopt Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Approve Remuneration Report COMPENSATION ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Approve Discharge of Management Board CORPORATE GOVERNANCE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Approve Discharge of Supervisory Board CORPORATE GOVERNANCE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Metin Colpan to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Toralf Haag to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Ross L. Levine to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Elaine Mardis to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Eva Pisa to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Lawrence A. Rosen to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Stephen H. Rusckowski to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Elizabeth E. Tallett to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Bert van Meurs to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Eva van Pelt to Supervisory Board DIRECTOR ELECTIONS ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Thierry Bernard to Management Board CORPORATE GOVERNANCE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reelect Roland Sackers to Management Board CORPORATE GOVERNANCE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Approve Remuneration Policy for the Supervisory Board COMPENSATION ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Approve Remuneration of Supervisory Board COMPENSATION ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Reappoint KPMG Accountants N.V. as Auditors for the Financial Year Ending December 31, 2024 AUDIT-RELATED ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Ratify Ernst & Young Accountants LLP as Auditors for the Financial Year Ending December 31, 2025 AUDIT-RELATED ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Grant Supervisory Board Authority to Issue Shares CAPITAL STRUCTURE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Authorize Supervisory Board to Exclude Preemptive Rights from Share Issuances CAPITAL STRUCTURE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Authorize Repurchase of Up to 10 Percent of Issued Share Capital CAPITAL STRUCTURE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Approve Discretionary Rights for the Managing Board to Implement Capital Repayment by Means of Synthetic Share Repurchase CAPITAL STRUCTURE ISSUER 644060.000000 0 FOR 644060.000000 FOR QIAGEN NV N72482149 NL0015001WM6 06/21/2024 Approve Cancellation of Shares CAPITAL STRUCTURE ISSUER 644060.000000 0 FOR 644060.000000 FOR CureVac NV N2451R105 NL0015436031 06/24/2024 Adopt Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 205163.000000 114960.000000 FOR 205163.000000 FOR CureVac NV N2451R105 NL0015436031 06/24/2024 Approve Discharge of Management Board CORPORATE GOVERNANCE ISSUER 205163.000000 114960.000000 FOR 205163.000000 FOR CureVac NV N2451R105 NL0015436031 06/24/2024 Approve Discharge of Supervisory Board CORPORATE GOVERNANCE ISSUER 205163.000000 114960.000000 FOR 205163.000000 FOR CureVac NV N2451R105 NL0015436031 06/24/2024 Elect Thaminda Ramanayake to Management Board CORPORATE GOVERNANCE ISSUER 205163.000000 114960.000000 FOR 205163.000000 FOR CureVac NV N2451R105 NL0015436031 06/24/2024 Reelect Malte Greune to Management Board CORPORATE GOVERNANCE ISSUER 205163.000000 114960.000000 FOR 205163.000000 FOR CureVac NV N2451R105 NL0015436031 06/24/2024 Reelect Jean Stephenne to Supervisory Board DIRECTOR ELECTIONS ISSUER 205163.000000 114960.000000 AGAINST 205163.000000 AGAINST CureVac NV N2451R105 NL0015436031 06/24/2024 Reelect Mathias Hothum to Supervisory Board DIRECTOR ELECTIONS ISSUER 205163.000000 114960.000000 AGAINST 205163.000000 AGAINST CureVac NV N2451R105 NL0015436031 06/24/2024 Elect Birgit Hofmann to Supervisory Board DIRECTOR ELECTIONS ISSUER 205163.000000 114960.000000 FOR 205163.000000 FOR CureVac NV N2451R105 NL0015436031 06/24/2024 Ratify KPMG N.V. as Auditors AUDIT-RELATED ISSUER 205163.000000 114960.000000 FOR 205163.000000 FOR Lexeo Therapeutics, Inc. 52886X107 US52886X1072 06/25/2024 The election of Mette Kirstine Agger as the Class I director: Mette Kirstine Agger DIRECTOR ELECTIONS ISSUER 26080.000000 0 FOR 26080.000000 FOR Lexeo Therapeutics, Inc. 52886X107 US52886X1072 06/25/2024 The ratification of the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 26080.000000 0 FOR 26080.000000 FOR SI-BONE, Inc. 825704109 US8257041090 06/25/2024 Election of Directors: Mika Nishimura DIRECTOR ELECTIONS ISSUER 204910.000000 0 FOR 204910.000000 FOR SI-BONE, Inc. 825704109 US8257041090 06/25/2024 Election of Directors: Thomas A. West DIRECTOR ELECTIONS ISSUER 204910.000000 0 FOR 204910.000000 FOR SI-BONE, Inc. 825704109 US8257041090 06/25/2024 To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as SI-BONE, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 204910.000000 0 FOR 204910.000000 FOR SI-BONE, Inc. 825704109 US8257041090 06/25/2024 Advisory vote to approve executive compensation "Say-on-Pay". SECTION 14A SAY-ON-PAY VOTES ISSUER 204910.000000 0 FOR 204910.000000 FOR SI-BONE, Inc. 825704109 US8257041090 06/25/2024 Approve an amendment to SI-BONE Inc.'s Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted pursuant to recent amendments to the Delaware General Corporation Law. CORPORATE GOVERNANCE ISSUER 204910.000000 0 FOR 204910.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/25/2024 Election of the nominee for Class I director named below to serve until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal: Sharon Tetlow DIRECTOR ELECTIONS ISSUER 155175.000000 103300.000000 FOR 155175.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/25/2024 To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 155175.000000 103300.000000 FOR 155175.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Christopher Causey DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Raymond Dwek DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Richard Giltner DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Ray Kurzweil DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Jan Malcolm DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Linda Maxwell DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Nilda Mesa DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Judy Olian DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Christopher Patusky DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Martine Rothblatt DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Louis Sullivan DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Election of Directors: Tommy Thompson DIRECTOR ELECTIONS ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Advisory resolution to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan. COMPENSATION ISSUER 55704.000000 0 FOR 55704.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2024. AUDIT-RELATED ISSUER 55704.000000 0 FOR 55704.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Approve Remuneration Report COMPENSATION ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Reappoint Ernst & Young LLP as Auditors and Authorise Their Remuneration AUDIT-RELATED ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Elect Director Linda Bain DIRECTOR ELECTIONS ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Elect Director Cynthia Butitta DIRECTOR ELECTIONS ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Elect Director Christian Itin DIRECTOR ELECTIONS ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Elect Director William Young DIRECTOR ELECTIONS ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Authorise Issue of Equity CAPITAL STRUCTURE ISSUER 765897.000000 0 FOR 765897.000000 FOR Autolus Therapeutics Plc 05280R100 US05280R1005 06/28/2024 Authorise Issue of Equity without Pre-emptive Rights CAPITAL STRUCTURE ISSUER 765897.000000 0 FOR 765897.000000 FOR